[CAS NO. 53-03-2] Prednisone
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [53-03-2]
Store
Catalog
HY-B0214
Brand
MCE
CAS
53-03-2
DESCRIPTION [53-03-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 358.43 |
| Molecular Formula | C21H26O5 |
| SMILES | C[C@@]1(C2)[C@](C(CO)=O)(O)CC[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3([H])C2=O)=O |
For research use only. We do not sell to patients.
3 Publications Citing Use of MCE
Summary
In Vivo
Prednisone (intramuscular injection, 10 mg/kg once a day, on days 4 to 13) reduces the survival rate on days lower than the control group in BALB/c mice with encephalomyocarditis virus myocarditis. Besides, myocardial virus titers reaches a maximum on day 4, but there is no antibody titer, and on day 8 virus titers remains elevated and antibody titers is also high. On day 10, antibody titers are significantly lower than controls, while viral titers remains significantly elevated
[2]
.
Prednisone (5 mg/kg, intragastrically administration, daily) can cause changes in FA metabolism in SLE mouse (MRL/lpr) model
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female MRL/lpr mice [3] |
| Dosage: | 5 mg/kg |
| Administration: | intragastrically administration, daily |
| Result: | Elevated polyunsaturated FA, such as arachidonic acid and docosahexaenoic acid, and reduced the total level of n-6 polyunsaturated fatty acidsin. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00736450 | University of Nebraska|National Cancer Institute (NCI)|Genta Incorporated |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
July 2008 | Not Applicable |
| NCT01940094 | University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Sciences (NCATS)|Rare Diseases Clinical Research Network |
Granulomatosis With Polyangiitis
|
February 2014 | Phase 3 |
| NCT02649413 | Rabin Medical Center |
Nephrotic Syndrome, Minimal Change
|
March 2016 | Phase 4 |
| NCT03625219 | Innovaderm Research Inc. |
Delayed Type Hypersensitivity
|
July 26, 2018 | Not Applicable |
| NCT01469338 | University of Southern California|National Cancer Institute (NCI)|Sanofi |
Diarrhea|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage IIA Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer
|
July 2012 | Phase 2 |
| NCT01193244 | Millennium Pharmaceuticals, Inc.|Takeda |
Prostate Cancer
|
October 1, 2010 | Phase 3 |
| NCT03016741 | Northwestern University |
Castration-Resistant Prostatic Cancer|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer|Hormone-Refractory Prostate Cancer
|
March 31, 2017 | Phase 4 |
| NCT02379390 | Sanofi |
Prostate Cancer Metastatic
|
June 17, 2015 | Phase 2 |
| NCT02458196 | Peking Union Medical College Hospital |
Autoimmune Disease
|
April 2015 | Phase 2 |
| NCT03748641 | Janssen Research & Development, LLC |
Castration-Resistant Prostatic Cancer
|
January 25, 2019 | Phase 3 |
| NCT00651755 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC |
Lymphoma
|
March 2008 | Not Applicable |
| NCT02792491 | Pusan National University Hospital |
Diffuse Large B-cell Lymphoma
|
August 2012 | Phase 2 |
| NCT02522715 | OHSU Knight Cancer Institute|Oregon Health and Science University |
Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer AJCC v7
|
October 13, 2015 | Phase 1|Phase 2 |
| NCT01746992 | Ruijin Hospital |
ALK-negative Anaplastic Large Cell Lymphoma|Peripherial T Cell Lymphoma,Not Otherwise Specified|Angioimmunoblastic T Cell Lymphoma|Enteropathy Associated T Cell Lymphoma|Hepatosplenic T Cell Lymphoma|Subcutaneous Panniculitis Like T Cell Lymphoma
|
September 2012 | Phase 4 |
| NCT00055640 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
October 2002 | Phase 2 |
| NCT01005316 | National Institute of Allergy and Infectious Diseases (NIAID)|National Heart, Lung, and Blood Institute (NHLBI) |
Pediatric Heart Transplantation|Pediatric Heart Transplant Recipients
|
January 2010 | |
| NCT02420717 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent Ph-Like Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Ph-Like Acute Lymphoblastic Leukemia
|
July 15, 2015 | Phase 2 |
| NCT00683475 | Eli Lilly and Company |
Prostate Cancer
|
August 2008 | Phase 2 |
| NCT03488225 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia in Remission|B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
March 28, 2018 | Phase 2 |
| NCT00362531 | Peking University |
Idiopathic Membranous Nephropathy|Nephrotic Syndrome
|
November 2004 | Phase 2|Phase 3 |
| NCT02367118 | University of Chile|Sociedad Chilena de Otorrinolaringología, Medicina y Cirugía de Cabeza y Cuello |
Sinusitis|Chronic Rhinosinusitis
|
June 2015 | Phase 3 |
| NCT04899570 | Peking Union Medical College Hospital |
Intravascular Large B-Cell Lymphoma
|
April 1, 2021 | Phase 2 |
| NCT03974867 | Eye & ENT Hospital of Fudan University |
Vestibular Vertigo|Sudden Hearing Loss
|
July 2019 | Not Applicable |
| NCT00828061 | Merck Sharp & Dohme LLC |
Allergic Rhinitis
|
February 4, 2009 | Phase 1 |
| NCT00015860 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
May 2001 | Phase 1|Phase 2 |
| NCT01468532 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer
|
October 2011 | Phase 1|Phase 2 |
| NCT00991939 | HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI) |
Immune Thrombocytopenic Purpura
|
January 2010 | Phase 3 |
| NCT00006721 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group |
Lymphoma
|
March 2001 | Phase 3 |
| NCT00003388 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
February 1999 | Phase 2 |
| NCT00109837 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
April 2005 | Phase 2 |
| NCT01692483 | Janssen Pharmaceutica |
Prostate Neoplasms
|
July 2013 | |
| NCT02268175 | Dana-Farber Cancer Institute|Medivation, Inc. |
Prostate Adenocarcinoma|Prostate Cancer|High Risk Prostate Cancer
|
October 2014 | Phase 2 |
| NCT00887198 | Janssen Research & Development, LLC |
Prostate Cancer
|
April 28, 2009 | Phase 3 |
| NCT01145508 | National Cancer Institute (NCI) |
Hormone-Resistant Prostate Cancer|Prostate Adenocarcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer
|
August 2010 | Phase 2 |
| NCT00350051 | Bayer |
Prostate Cancer
|
August 1, 2006 | Phase 2 |
| NCT03223610 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma|Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Burkitt Lymphoma
|
February 9, 2018 | Phase 1|Phase 2 |
| NCT05084859 | Biosplice Therapeutics, Inc. |
Castration-resistant Prostate Cancer|Non-small Cell Lung Cancer|Colorectal Cancer
|
November 3, 2021 | Phase 1 |
| NCT00059839 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
November 2003 | Phase 3 |
| NCT00363090 | Toronto Sunnybrook Regional Cancer Centre|National Cancer Institute (NCI) |
Lymphoma
|
September 2006 | Phase 1|Phase 2 |
| NCT01666314 | Millennium Pharmaceuticals, Inc.|Takeda |
Prostate Cancer
|
August 20, 2012 | Phase 1|Phase 2 |
| NCT00119678 | Bristol-Myers Squibb |
Systemic Lupus Erythematosus
|
September 2005 | Phase 2 |
| NCT00809341 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Genentech, Inc. |
Non-Hodgkin´s Lymphoma
|
January 2009 | Phase 2 |
| NCT00136903 | Mesoblast, Inc.|Mesoblast, Ltd. |
Graft Vs Host Disease
|
April 27, 2005 | Phase 2 |
| NCT03003520 | Celgene |
Lymphoma, Large B-Cell, Diffuse
|
February 28, 2017 | Phase 2 |
| NCT00494897 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 1996 | Phase 4 |
| NCT01240850 | University of Parma |
Idiopathic Retroperitoneal Fibrosis|Perianeurysmal Retroperitoneal Fibrosis|Chronic Periaortitis
|
May 2007 | Phase 3 |
| NCT00414414 | Ottawa Hospital Research Institute|Ontario Lung Association |
Tuberculosis|HIV Infections
|
February 2007 | Phase 3 |
| NCT00088881 | National Cancer Institute (NCI) |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia
|
December 2004 | Phase 2 |
| NCT04850495 | Yazeed Sawalha|Ohio State University Comprehensive Cancer Center |
Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
|
November 16, 2021 | Phase 1 |
| NCT02867020 | Latin American Cooperative Oncology Group|Janssen Pharmaceuticals |
Prostate Cancer
|
October 11, 2017 | Phase 2 |
| NCT00020943 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
June 2001 | Phase 2 |
| NCT02959944 | Pharmacyclics LLC.|Janssen Research & Development, LLC |
Chronic Graft Versus Host Disease
|
May 11, 2017 | Phase 3 |
| NCT00879619 | John P. Fruehauf|Sanofi|University of California, Irvine |
Prostate Cancer|Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer
|
July 2009 | Phase 1|Phase 2 |
| NCT05594784 | Institute of Hematology & Blood Diseases Hospital |
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
|
October 8, 2022 | Phase 2 |
| NCT01155791 | Sandy Srinivas|Stanford University |
Urologic Neoplasms|Prostate Cancer|Prostate Cancer Metastatic Disease
|
April 2010 | Phase 1 |
| NCT00265031 | University of Cologne |
Hodgkin´s Lymphoma
|
January 1999 | Phase 3 |
| NCT03711448 | Centre Hospitalier Universitaire Dijon |
Patients Relapsing Refractory Giant Cell Arteritis
|
January 7, 2019 | Phase 2 |
| NCT02753647 | Ruijin Hospital |
Diffuse Large B-cell Lymphoma
|
April 2016 | Phase 2 |
| NCT01332097 | Novartis Pharmaceuticals|Novartis |
Chronic Obstructive Pulmonary Disease
|
March 2011 | Phase 2 |
| NCT00425724 | Oulu University Hospital |
Purpura, Schoenlein-Henoch
|
January 2000 | Phase 4 |
| NCT04978584 | M.D. Anderson Cancer Center |
Diffuse Large B-Cell Lymphoma
|
March 3, 2022 | Phase 2 |
| NCT00238368 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
February 2004 | Phase 2 |
| NCT01321008 | M.D. Anderson Cancer Center |
Lymphoma
|
May 2011 | Phase 1|Phase 2 |
| NCT01933724 | University of South Florida|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Sciences (NCATS)|Rare Diseases Clinical Research Network |
Granulomatosis With Polyangiitis|Wegener Granulomatosis|Vasculitis
|
February 17, 2014 | Phase 3 |
| NCT01075711 | Merck KGaA, Darmstadt, Germany|Merck Serono GmbH, Germany |
Arthritis, Rheumatoid
|
April 2009 | |
| NCT03565835 | Montefiore Medical Center |
Prostatic Neoplasms
|
June 13, 2018 | Phase 2 |
| NCT01087580 | Northwestern University|Genzyme, a Sanofi Company |
PROSTATE CANCER
|
March 2011 | Phase 2 |
| NCT01981889 | University of British Columbia |
Inflammatory Bowel Disease 11
|
October 2013 | Phase 4 |
| NCT04659915 | Eleonora Seelig|University Hospital, Basel, Switzerland |
Glucocorticoid Effect
|
February 25, 2021 | Phase 4 |
| NCT00508040 | Assistance Publique - Hôpitaux de Paris |
Birdshot Chorioretinopathy|Cystoid Macular Edema|Transient Partial Visual Loss
|
September 2007 | Phase 2 |
| NCT00298324 | European Society for Blood and Marrow Transplantation|Novartis |
Graft vs Host Disease
|
September 2006 | Phase 3 |
| NCT01054144 | H. Lee Moffitt Cancer Center and Research Institute|Celgene |
Multiple Myeloma
|
January 14, 2010 | Phase 2 |
| NCT00485303 | Cougar Biotechnology, Inc. |
Prostatic Neoplasms|Prostate Cancer
|
June 2007 | Phase 2 |
| NCT01414855 | Genentech, Inc. |
Lymphoma, B-Cell
|
August 31, 2011 | Phase 2 |
| NCT02188719 | National Institute of Allergy and Infectious Diseases (NIAID)|Rho Federal Systems Division, Inc. |
Liver Transplantation
|
December 17, 2014 | Phase 1 |
| NCT02550652 | Hoffmann-La Roche |
Lupus Nephritis
|
November 13, 2015 | Phase 2 |
| NCT01974440 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Lymphoma
|
January 31, 2014 | Phase 3 |
| NCT00017290 | Genitope Corporation|National Cancer Institute (NCI) |
Lymphoma
|
November 2000 | Phase 3 |
| NCT00004124 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B |
Prostate Cancer
|
October 1999 | Phase 3 |
| NCT03834506 | Merck Sharp & Dohme LLC |
Prostatic Neoplasms
|
May 2, 2019 | Phase 3 |
| NCT00005959 | Amgen|National Cancer Institute (NCI) |
Lymphoma
|
December 1999 | Phase 2 |
| NCT00307645 | Assistance Publique - Hôpitaux de Paris |
ANCA Associated Systemic Vasculitis Including Wegener´s|Granulomatosis and Microscopic Polyangiitis and|Renal Limited Vasculitis
|
May 2003 | Phase 3 |
| NCT00466440 | Eli Lilly and Company |
Prostate Cancer
|
June 2007 | Phase 2 |
| NCT02767089 | Pfizer |
Healthy Adults
|
October 2005 | Phase 1 |
| NCT00258388 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Prostate Cancer
|
June 27, 2005 | Phase 2 |
| NCT00194987 | Weill Medical College of Cornell University|New York Presbyterian Hospital|Columbia University |
Alloimmune Thrombocytopenia|Fetal Alloimmune Thrombocytopenia
|
April 2001 | Phase 2|Phase 3 |
| NCT01695005 | Eli Lilly and Company |
Neoplasms|Neoplasm Metastasis|Lymphoma
|
October 2012 | Phase 1 |
| NCT02683291 | Associação Médico Espírita de Botucatu |
Disorder Related to Renal Transplantation|Cytomegalovirus Infections
|
January 2014 | Phase 4 |
| NCT00002462 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma
|
September 1989 | Phase 3 |
| NCT05351346 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
June 1, 2022 | Phase 3 |
| NCT00651040 | Institute of Rheumatology, Prague|Karolinska Institutet |
Polymyositis|Dermatomyositis
|
May 2008 | Phase 3 |
| NCT04151082 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Cranial Nerve Disorder|Head and Neck Carcinoma|Oropharyngeal Carcinoma
|
October 31, 2019 | Phase 1|Phase 2 |
| NCT04100018 | Bristol-Myers Squibb |
Prostate Cancer
|
February 6, 2020 | Phase 3 |
| NCT03827473 | University of Utah |
Castration-Sensitive Prostate Carcinoma|Metastatic Prostatic Adenocarcinoma|Stage IV Prostate Cancer|Stage IVA Prostate Cancer|Stage IVB Prostate Cancer
|
February 8, 2019 | Phase 2 |
| NCT00146640 | Merck KGaA, Darmstadt, Germany |
Rheumatoid Arthritis
|
August 31, 2004 | Phase 3 |
| NCT05095961 | Loma Linda University |
Chronic Sinus Disease|Chronic Sinusitis, Ethmoidal|Chronic Sinusitis, Sphenoidal|Chronic Sinusitis - Maxillary Bilateral|Chronic Sinusitis - Frontoethmoidal
|
March 2023 | Phase 2|Phase 3 |
| NCT00293371 | University of California, San Francisco|National Cancer Institute (NCI) |
Prostate Cancer
|
February 2005 | Phase 1|Phase 2 |
| NCT03419234 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma in the Soft Tissue|Prostate Carcinoma Metastatic in the Bone|Stage IV Prostate Adenocarcinoma AJCC v7
|
February 8, 2018 | Phase 2 |
| NCT00644306 | Central Hospital, Nancy, France |
Newly Diagnosed, Multiple Myeloma
|
April 2002 | Phase 3 |
| NCT03970577 | Assistance Publique - Hôpitaux de Paris |
Minimal Change Nephrotic Syndrome (MCNS)
|
July 29, 2020 | Phase 2 |
| NCT01650194 | Astellas Pharma Global Development, Inc.|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.|Astellas Pharma Inc |
Metastatic Castration-Resistant Prostate Cancer
|
July 9, 2012 | Phase 2 |
| NCT01900431 | Sanofi |
Uveitis
|
October 2013 | Phase 2 |
| NCT02058875 | University of Saskatchewan |
Cardiovascular Disease|Cardiovascular Outcomes|Kidney Transplant Recipients|Kidney Transplantation
|
February 2014 | Phase 4 |
| NCT04497844 | Janssen Research & Development, LLC |
Metastatic Castrate Sensitive Prostate Cancer
|
September 23, 2020 | Phase 3 |
| NCT05049473 | PETHEMA Foundation|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
Mature B-Cell Leukemia Burkitt Type|Burkitt Lymphoma (BL)|Unclassifiable Lymphoma Between DCBL and BL
|
January 2014 | Phase 2 |
| NCT01407484 | Assistance Publique - Hôpitaux de Paris |
Male Infertility|Leukopenia|Postinfection Inflammation|Oxidative Stress
|
March 2, 2011 | Not Applicable |
| NCT03726749 | Massachusetts General Hospital|Roche-Genentech |
Giant Cell Arteritis
|
November 28, 2018 | Phase 4 |
| NCT00088530 | CTI BioPharma |
Lymphoma, Non-Hodgkin
|
July 2004 | Phase 3 |
| NCT00734149 | Duke University |
Multiple Myeloma
|
July 2004 | Phase 2 |
| NCT00374231 | University of Cincinnati|Astellas Pharma Inc |
Liver Transplantation
|
October 2002 | Phase 4 |
| NCT00133172 | Astellas Pharma Inc|Astellas Pharma Canada, Inc. |
Kidney Transplantation
|
July 2005 | Phase 4 |
| NCT03692416 | Assiut University |
Vasculitis
|
November 11, 2018 | Phase 3 |
| NCT00255606 | Tampere University|National Cancer Institute (NCI) |
Prostate Cancer
|
August 2005 | Phase 3 |
| NCT03593759 | Ottawa Heart Institute Research Corporation|Canadian Institutes of Health Research (CIHR) |
Cardiac Sarcoidosis|Sarcoidosis
|
January 15, 2019 | Phase 3 |
| NCT01133275 | H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation |
Myelodysplastic Syndrome|MDS
|
April 28, 2010 | Phase 2 |
| NCT03492255 | University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo |
Systemic Lupus Erythematosus (SLE)
|
April 12, 2018 | Not Applicable |
| NCT02636322 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma Unclassifiable
|
March 29, 2016 | Phase 2 |
| NCT04376216 | Region MidtJylland Denmark|Aarhus University Hospital|Odense University Hospital |
Acute Tubulo-Interstitial Nephritis
|
September 1, 2017 | Phase 4 |
| NCT01204710 | Eli Lilly and Company |
Prostate Cancer
|
October 2010 | Phase 2 |
| NCT00556127 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie |
Diffuse Large B-Cell Lymphoma|POOR PROGNOSIS
|
June 2002 | Phase 2 |
| NCT00317447 | Kaiser Permanente |
Sciatica
|
February 2002 | Phase 3 |
| NCT01591122 | Janssen Research & Development, LLC |
Prostate Cancer
|
March 27, 2012 | Phase 3 |
| NCT01392833 | A. Manzoni Hospital |
IgA Nephropathy|Chronic Kidney Disease
|
December 1999 | Phase 3 |
| NCT02748070 | Stanford University |
Chronic Rhinosinusitis|Endoscopic Sinus Surgery|Chronic Rhinosinusitis Without Polyps|Oral Steroids
|
August 2015 | Not Applicable |
| NCT03139604 | Incyte Corporation |
Graft-versus-host Disease (GVHD)
|
July 19, 2017 | Phase 3 |
| NCT00092222 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoproliferative Disorder|HHV-8|Malignancy|HIV
|
October 28, 2004 | Phase 2 |
| NCT01715285 | Janssen Research & Development, LLC |
Prostate Neoplasms
|
February 2013 | Phase 3 |
| NCT00480272 | IRCCS Policlinico S. Matteo |
Rheumatoid Arthritis
|
May 2007 | Phase 4 |
| NCT04305145 | Massachusetts General Hospital |
Melanoma Stage III|Melanoma Stage IV|Side Effect of Drug|Colitis
|
August 31, 2020 | Phase 2 |
| NCT01637402 | Terence Friedlander, MD|Janssen Biotech, Inc.|University of California, San Francisco |
Castration Resistant Prostate Cancer
|
March 13, 2013 | Phase 2 |
| NCT00002514 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Medical Research Council |
Leukemia
|
April 1993 | Phase 3 |
| NCT02344017 | Orion Corporation, Orion Pharma |
Prostate Cancer
|
February 2015 | Phase 1|Phase 2 |
| NCT00268567 | Peking University |
Nephritis, Lupus
|
October 2002 | Phase 2|Phase 3 |
| NCT01186328 | Therapeutic Advances in Childhood Leukemia Consortium|Enzon Pharmaceuticals, Inc. |
Lymphoblastic Leukemia, Acute|Lymphoblastic Leukemia, Acute, Childhood|Leukemia, Lymphoblastic, Acute, T Cell|Leukemia, Lymphoblastic, Acute
|
August 24, 2010 | Phase 1 |
| NCT04492358 | Maria Joyera Rodríguez|Fundacion Clinic per a la Recerca Biomédica |
Covid19
|
October 22, 2020 | Phase 2|Phase 3 |
| NCT04440267 | wang, jianxiang|Institute of Hematology & Blood Diseases Hospital |
Acute Leukemia of Ambiguous Lineage
|
June 20, 2020 | Phase 2 |
| NCT04577833 | Janssen Research & Development, LLC |
Prostatic Neoplasms
|
November 13, 2020 | Phase 1 |
| NCT02543255 | University Health Network, Toronto |
Prostate Cancer
|
September 2016 | Phase 2 |
| NCT00000819 | National Institute of Allergy and Infectious Diseases (NIAID)|Upjohn |
HIV Infections|AIDS-Associated Nephropathy
|
Phase 2 | |
| NCT00187122 | St. Jude Children´s Research Hospital |
Lymphoblastic Lymphoma
|
March 1993 | Not Applicable |
| NCT04357392 | chenfengling|Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University |
Diabetes Mellitus, Type 2
|
May 20, 2020 | Early Phase 1 |
| NCT00294658 | University of Alabama at Birmingham|National Institute of Neurological Disorders and Stroke (NINDS) |
Myasthenia Gravis
|
June 2006 | Phase 3 |
| NCT02074137 | Sanofi |
Prostate Cancer Metastatic
|
July 2014 | Phase 4 |
| NCT01169597 | University of Genova |
Polymyalgia Rheumatica
|
January 2009 | Phase 4 |
| NCT00060346 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
June 2004 | Phase 2 |
| NCT02337985 | City of Hope Medical Center|National Cancer Institute (NCI) |
AIDS-Related Burkitt Lymphoma|AIDS-Related Diffuse Large B-cell Lymphoma|AIDS-Related Plasmablastic Lymphoma|AIDS-Related Primary Effusion Lymphoma|HIV Infection|AIDS Related Non-Hodgkin Lymphoma
|
November 20, 2015 | Phase 1 |
| NCT02195479 | Janssen Research & Development, LLC |
Multiple Myeloma
|
December 9, 2014 | Phase 3 |
| NCT01183247 | University Hospital, Basel, Switzerland|Novartis |
Comparative Study|Immunosuppressive Agents
|
July 2008 | Phase 4 |
| NCT00988208 | Celgene |
Prostate Cancer
|
November 11, 2009 | Phase 3 |
| NCT00381680 | Children´s Oncology Group|National Cancer Institute (NCI) |
B-cell Childhood Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
|
March 2007 | Phase 3 |
| NCT00134056 | Southwest Oncology Group|National Cancer Institute (NCI) |
Metastatic Cancer|Prostate Cancer
|
August 2006 | Phase 3 |
| NCT00715715 | Maimonides Medical Center |
Chronic Hepatitis B
|
April 2008 | Not Applicable |
| NCT01332968 | Hoffmann-La Roche|German Low Grade Lymphoma Study Group|Institute of Cancer Research, United Kingdom |
Non-Hodgkin´s Lymphoma
|
July 6, 2011 | Phase 3 |
| NCT02994927 | ChemoCentryx |
ANCA-Associated Vasculitis
|
March 15, 2017 | Phase 3 |
| NCT00003150 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Southwest Oncology Group |
Lymphoma
|
December 1997 | Phase 3 |
| NCT05591144 | Eye & ENT Hospital of Fudan University |
Tinnitus, Subjective|Hearing Loss, Sensorineural
|
July 1, 2022 | Not Applicable |
| NCT03099122 | Sanofi |
End-stage Renal Disease
|
August 16, 2017 | Phase 4 |
| NCT03161054 | Fondazione Italiana Linfomi ONLUS |
Aggressive Non-Hodgkin Lymphoma
|
September 12, 2017 | Phase 2 |
| NCT00004179 | European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Stichting Hemato-Oncologie voor Volwassenen Nederland|Australasian Leukaemia and Lymphoma Group|NCIC Clinical Trials Group|Nordic Lymphoma Group |
Lymphoma
|
May 1999 | Phase 3 |
| NCT00311311 | Pfizer |
Atherosclerosis|Kidney Failure
|
April 2006 | Phase 3 |
| NCT00463385 | Celgene |
Myelofibrosis With Myeloid Metaplasia|Myeloid Metaplasia|Myelofibrosis
|
April 1, 2007 | Phase 2 |
| NCT02449252 | Wuhan University |
Follicular Lymphoma
|
October 2015 | Phase 3 |
| NCT00211185 | Eisai Inc. |
Lymphoma, T-Cell, Peripheral
|
March 14, 2004 | Phase 2 |
| NCT01834209 | Janssen Research & Development, LLC |
Prostate Neoplasms
|
||
| NCT02703623 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|PSA Progression|Stage IV Prostate Adenocarcinoma AJCC v7
|
May 18, 2016 | Phase 2 |
| NCT00324831 | Favrille|National Cancer Institute (NCI) |
Lymphoma
|
Phase 3 | |
| NCT03804931 | Guangzhou First People´s Hospital |
Ulcerative Colitis|Fecal Microbiota Transplantation
|
January 20, 2019 | Phase 2|Phase 3 |
| NCT00841945 | French Innovative Leukemia Organisation |
B Cell Lymphoma
|
April 2005 | Phase 3 |
| NCT03436654 | Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute |
Prostate Cancer
|
June 21, 2018 | Phase 2 |
| NCT03591471 | Henan University of Traditional Chinese Medicine|Peking University First Hospital|Children´s Hospital of Fudan University|Shanghai Children´s Hospital|Chengdu University of Traditional Chinese Medicine|Affiliated Hospital of Yunnan University of Traditional Chinese Medicine |
Henoch-Schönlein Purpura Nephritis
|
September 2014 | Phase 1|Phase 2 |
| NCT03279250 | M.D. Anderson Cancer Center |
Prostate Adenocarcinoma|Stage IIB Prostate Cancer AJCC v8|Stage IIC Prostate Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8
|
October 13, 2017 | Phase 2 |
| NCT00717470 | Astellas Pharma Inc |
Kidney Transplantation
|
May 14, 2008 | Phase 4 |
| NCT01349270 | Centre Hospitalier Universitaire de Saint Etienne|Laboratoire français de Fractionnement et de Biotechnologies |
Demyelinating Polyneuropathy
|
June 2004 | Phase 3 |
| NCT01424930 | Janssen-Ortho Inc., Canada |
Prostate Neoplasms|Prostate Cancer
|
October 2011 | Phase 2 |
| NCT03704714 | Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI) |
Aggressive Non-Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|CD20 Positive|Diffuse Large B-Cell Lymphoma Unclassifiable|Intravascular Large B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
|
November 20, 2018 | Phase 1|Phase 2 |
| NCT00003215 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
April 1997 | Phase 3 |
| NCT00451178 | Eli Lilly and Company |
Lymphoma
|
May 2007 | Phase 2 |
| NCT01042145 | Washington University School of Medicine|Washington University Pediatric and Adolescent Ambulatory Research Consortium |
Croup
|
October 2009 | Phase 4 |
| NCT04918147 | National Institute of Allergy and Infectious Diseases (NIAID)|Autoimmunity Centers of Excellence|Bristol-Myers Squibb|Rho Federal Systems Division, Inc. |
IgG4 Related Disease|IgG4-RD
|
October 13, 2021 | Phase 2 |
| NCT00110214 | National Cancer Institute (NCI) |
Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer
|
April 2005 | Phase 3 |
| NCT00668434 | Kaiser Permanente|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Sciatica
|
November 2008 | Phase 2 |
| NCT05453500 | University of Washington|Incyte Corporation |
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
January 1, 2023 | Phase 2 |
| NCT03384654 | Janssen Research & Development, LLC |
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
May 14, 2018 | Phase 2 |
| NCT00034528 | National Institute of Allergy and Infectious Diseases (NIAID) |
Hemoglobinopathies|Anemia, Sickle Cell|Hemoglobin SC Disease|Thalassemia|Thalassemia Major
|
September 2001 | Phase 2 |
| NCT02506192 | Minneapolis Veterans Affairs Medical Center|United States Department of Defense |
Chronic Inflammation|Chronic Pain|Fatigue|Cognitive Impairment
|
July 2015 | Phase 2 |
| NCT00472030 | University of Iowa|Genentech, Inc. |
Bullous Pemphigoid
|
August 2007 | Phase 4 |
| NCT02927834 | Loma Linda University |
Sinusitis
|
August 2015 | Not Applicable |
| NCT00165178 | Dana-Farber Cancer Institute|Boston Children´s Hospital|University of Rochester|McMaster University|San Jorge Children´s Hospital (Puerto Rico)|St. Justine´s Hospital|Maine Children´s Cancer Program|Ochsner Health System|Tulane University School of Medicine|Laval University|Columbia University |
Acute Lymphoblastic Leukemia
|
September 2000 | Phase 3 |
| NCT03298698 | Radboud University Medical Center |
Idiopathic Nephrotic Syndrome|Minimal Change Disease|Focal Segmental Glomerulosclerosis
|
August 22, 2018 | Phase 3 |
| NCT00413920 | Novartis |
Renal Transplantation
|
April 2007 | Phase 3 |
| NCT01837433 | Xinqiao Hospital of Chongqing |
Subacute Thyroiditis
|
March 2013 | Phase 4 |
| NCT00003389 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 1999 | Phase 3 |
| NCT02913196 | Weill Medical College of Cornell University|Janssen Scientific Affairs, LLC |
Prostate Cancer Metastatic
|
December 30, 2016 | Phase 1 |
| NCT00284271 | University of Cologne |
Hodgkin´s Lymphoma
|
January 2004 | Phase 2 |
| NCT00428142 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Lymphoma
|
December 2006 | Phase 2 |
| NCT00003700 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia
|
January 1999 | Phase 2 |
| NCT00822120 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma|Nonneoplastic Condition
|
July 2009 | Phase 2 |
| NCT04951986 | University of Cape Town |
Disseminated Tuberculosis|HIV
|
August 11, 2021 | Phase 3 |
| NCT01464164 | Northwell Health |
Diamond Blackfan Anemia
|
January 2012 | Phase 1|Phase 2 |
| NCT02449278 | Wuhan University |
Diffuse Large B-cell Lymphoma
|
October 2015 | Phase 3 |
| NCT00053768 | German High-Grade Non-Hodgkin´s Lymphoma Study Group|Universität des Saarlandes |
Lymphoma
|
April 2002 | Phase 3 |
| NCT00074490 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma|Leukemia|Myeloproliferative Disorders|Multiple Myleoma|Myelodysplastic Syndrome
|
January 1, 2004 | Phase 2 |
| NCT03023891 | Vanderbilt University Medical Center|National Institute of General Medical Sciences (NIGMS) |
Glucocorticoids Toxicity|Glucose Intolerance
|
February 15, 2017 | Phase 1 |
| NCT04628988 | Celgene |
Prostatic Neoplasms
|
July 28, 2021 | Phase 1 |
| NCT00890617 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Lung Cancer|Metastatic Cancer
|
March 2009 | Phase 1 |
| NCT00911183 | Institut Bergonié|National Cancer Institute, France |
Lymphoma
|
December 2, 2008 | Phase 2 |
| NCT05295927 | Janssen Research & Development, LLC |
Prostatic Neoplasms
|
March 23, 2022 | Phase 1 |
| NCT02531308 | Rush University Medical Center |
Diffuse Large B-Cell Lymphoma
|
July 2015 | Phase 2 |
| NCT05090384 | John Levine|Icahn School of Medicine at Mount Sinai |
Acute Graft vs Host Disease|Allogeneic Bone Marrow Transplantation|Adverse Effects
|
September 2022 | Phase 2 |
| NCT02428751 | Wenqi Jiang|Sun Yat-sen University |
Lymphoma, Large B-Cell, Diffuse
|
September 2015 | Phase 3 |
| NCT00812123 | University Hospital, Basel, Switzerland|Wyeth is now a wholly owned subsidiary of Pfizer |
Kidney Transplantation|Chronic Kidney Disease
|
January 2001 | Phase 4 |
| NCT00049036 | National Cancer Institute (NCI) |
AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Peripheral+Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma
|
March 2003 | Phase 2 |
| NCT03819296 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Clinical Stage 0 Cutaneous Melanoma AJCC v8|Clinical Stage I Cutaneous Melanoma AJCC v8|Clinical Stage IA Cutaneous Melanoma AJCC v8|Clinical Stage IB Cutaneous Melanoma AJCC v8|Clinical Stage II Cutaneous Melanoma AJCC v8|Clinical Stage IIA Cutaneous Melanoma AJCC v8|Clinical Stage IIB Cutaneous Melanoma AJCC v8|Clinical Stage IIC Cutaneous Melanoma AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Colitis|Lung Non-Small Cell Carcinoma|Malignant Genitourinary System Neoplasm|Malignant Solid Neoplasm|Pathologic Stage 0 Cutaneous Melanoma AJCC v8|Pathologic Stage I Cutaneous Melanoma AJCC v8|Pathologic Stage IA Cutaneous Melanoma AJCC v8|Pathologic Stage IB Cutaneous Melanoma AJCC v8|Pathologic Stage II Cutaneous Melanoma AJCC v8|Pathologic Stage IIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIC Cutaneous Melanoma AJCC v8|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Stage 0 Lung Cancer AJCC v8|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
February 21, 2021 | Phase 1|Phase 2 |
| NCT00057811 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Untreated Childhood Acute Lymphoblastic Leukemia
|
June 2004 | Phase 2 |
| NCT00494780 | GlaxoSmithKline |
Lymphoma, Follicular
|
June 2007 | Phase 2 |
| NCT00689845 | University Hospital Southampton NHS Foundation Trust|National Cancer Institute (NCI) |
Lymphoma
|
June 2007 | Not Applicable |
| NCT02855359 | Seagen Inc. |
Diffuse, Large B-Cell, Lymphoma|Follicular Lymphoma, Grade 3b|Transformed Lymphoma + DLBCL
|
August 2016 | Phase 2 |
| NCT01364389 | Novartis Pharmaceuticals|Novartis |
Polymyalgia Rheumatica|Inflammatory Diseases
|
February 14, 2011 | Phase 2 |
| NCT00577993 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
March 16, 1998 | Phase 3 |
| NCT00911859 | Janssen Research & Development, LLC |
Multiple Myeloma
|
June 2009 | Phase 2 |
| NCT00390793 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|BCR-ABL1 Fusion Protein Expression|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|t(9;22)
|
September 28, 2006 | Phase 2 |
| NCT00956059 | Health Science Center of Xi´an Jiaotong University |
Focal Segmental Glomerulosclerosis
|
September 2009 | Not Applicable |
| NCT01023061 | University of Washington|National Cancer Institute (NCI) |
Adenocarcinoma of the Prostate|Stage II Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer
|
March 2010 | Phase 2 |
| NCT03218852 | Guangdong Provincial People´s Hospital |
IgA Nephropathy
|
December 2016 | Phase 4 |
| NCT00722137 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Takeda |
Mantle Cell Lymphoma
|
May 1, 2008 | Phase 3 |
| NCT02429193 | University Health Network, Toronto |
Castration-resistant Prostate Cancer
|
March 2016 | Phase 2 |
| NCT03777982 | Dana-Farber Cancer Institute|Janssen Scientific Affairs, LLC |
Prostate Cancer
|
April 20, 2020 | Phase 3 |
| NCT01166113 | Fondazione EMN Italy Onlus |
Multiple Myeloma
|
July 2010 | Phase 1|Phase 2 |
| NCT00045500 | National Cancer Institute (NCI) |
Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific
|
June 2002 | Phase 1 |
| NCT00002812 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
September 1996 | Phase 3 |
| NCT00934791 | Mayo Clinic|Wyeth is now a wholly owned subsidiary of Pfizer |
Polycystic Liver Disease
|
February 2009 | Not Applicable |
| NCT04446117 | Exelixis|Roche-Genentech|Takeda |
Metastatic Prostate Cancer|Prostate Adenocarcinoma
|
June 30, 2020 | Phase 3 |
| NCT05458180 | Tianjin Medical University Cancer Institute and Hospital|CSPC Ouyi Pharmaceutical Co., Ltd. |
Peripheral T-cell Lymphoma
|
July 7, 2022 | Phase 1 |
| NCT02034552 | Bayer |
Prostatic Neoplasms
|
March 7, 2014 | Phase 2 |
| NCT01116128 | Fondazione EMN Italy Onlus |
Myeloma
|
February 2008 | Phase 2 |
| NCT00838214 | Dr. Falk Pharma GmbH |
Autoimmune Hepatitis
|
March 2001 | Phase 2|Phase 3 |
| NCT03018626 | Nanfang Hospital of Southern Medical University |
Lymphoma, Large B-Cell, Diffuse
|
July 27, 2017 | Phase 3 |
| NCT02523976 | Institute of Hematology & Blood Diseases Hospital |
Acute,Leukemia, Lymphoid
|
August 1, 2015 | Phase 2 |
| NCT00278421 | German High-Grade Non-Hodgkin´s Lymphoma Study Group |
Lymphoma
|
November 2005 | Phase 3 |
| NCT00005603 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
March 2000 | Phase 3 |
| NCT01335685 | Millennium Pharmaceuticals, Inc.|Takeda |
Multiple Myeloma
|
June 27, 2011 | Phase 1|Phase 2 |
| NCT02703376 | Nagasaki University |
Esophageal Anastomotic Stricture
|
January 2016 | Phase 1 |
| NCT00004039 | Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group |
Lymphoma
|
June 1998 | Phase 2 |
| NCT00450385 | University of Miami |
Lymphoma
|
April 24, 2007 | Phase 2 |
| NCT03039608 | Shanghai Zhongshan Hospital |
Esophageal Stricture
|
February 10, 2017 | Not Applicable |
| NCT01758393 | Peking Union Medical College Hospital |
IgG4-related Disease
|
December 2012 | Phase 2|Phase 3 |
| NCT00613457 | Associazione Italiana Ematologia Oncologia Pediatrica |
Leukemia
|
September 2000 | Phase 3 |
| NCT03677141 | Hoffmann-La Roche |
B-cell Non-Hodgkin Lymphoma
|
February 8, 2019 | Phase 1|Phase 2 |
| NCT04083898 | Washington University School of Medicine|Sanofi |
Multiple Myeloma
|
April 3, 2020 | Phase 1|Phase 2 |
| NCT00193479 | SCRI Development Innovations, LLC|Genentech, Inc.|Amgen |
Non-Hodgkins Lymphoma
|
April 2003 | Phase 2 |
| NCT00004232 | Northwestern University|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous+Nonmalignant Condition
|
October 1999 | Phase 1 |
| NCT00746512 | Merck Sharp & Dohme LLC |
Rheumatoid Arthritis
|
September 2008 | Phase 1 |
| NCT05371054 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma|Non-Hodgkin Lymphoma|NHL|Hematologic Malignancies|Lymphoid Malignancies
|
November 28, 2022 | Phase 1|Phase 2 |
| NCT05059873 | Capital Medical University|Peking University|Guang´anmen Hospital of China Academy of Chinese Medical Sciences|Xuanwu Hospital, Beijing|Beijing Anzhen Hospital|Beijing Tongren Hospital|Beijing Luhe Hospital|Emergency General Hospital|Beijing Jishuitan Hospital|Beijing Jingmei Group Hospital|Beijing Shijingshan Hospital|Bejing INFI-SAGACITY TECHNOLOGY CO., LTD|Chinese People´s Liberation Army of China General Hospital |
Acute Exacerbation of COPD|Corticosteroid|Morality|Lung Diseases, Obstructive|Blood Eosinophil Count|COPD|Pulmonary Disease, Chronic Obstructive
|
October 10, 2022 | Phase 4 |
| NCT03833921 | Martha Mims|Baylor College of Medicine |
Prostate Cancer Metastatic|Prostate Cancer
|
May 23, 2019 | Phase 2 |
| NCT02954198 | Medical University of South Carolina |
Immunosuppression
|
December 1, 2016 | Not Applicable |
| NCT00825149 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
February 2009 | Phase 1 |
| NCT01241006 | Alameda County Medical Center |
Asthma|Reactive Airway Disease
|
January 2011 | Phase 4 |
| NCT00058422 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
February 10, 2003 | Phase 2 |
| NCT00005578 | Children´s Oncology Group|National Cancer Institute (NCI) |
Cardiac Toxicity|Lymphoma
|
March 1997 | Phase 3 |
| NCT00182741 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Prostate Cancer
|
September 2004 | Phase 2 |
| NCT03165344 | Peking University Third Hospital |
Esophageal Stenosis Acquired
|
February 10, 2017 | Not Applicable |
| NCT00526175 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 2001 | Phase 4 |
| NCT01415765 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma, Diffuse Large-Cell B-cell|Diffuse, Large B-cell Lymphoma|Lymphoma, Diffuse Large-Cell|Large-Cell Lymphoma, Diffuse
|
July 15, 2011 | Phase 1|Phase 2 |
| NCT00924469 | Janssen Research & Development, LLC |
Prostate Cancer
|
November 2009 | Phase 2 |
| NCT02451748 | University of Illinois at Chicago|UCB Pharma |
Rheumatoid Arthritis
|
August 2015 | Phase 4 |
| NCT03466801 | Wenhu Liu|Beijing Friendship Hospital |
Idiopathic Membranous Nephropathy
|
March 20, 2018 | Not Applicable |
| NCT00972478 | National Cancer Institute (NCI) |
Ann Arbor Stage II Non-Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma
|
November 15, 2010 | Phase 1|Phase 2 |
| NCT02763761 | Bristol-Myers Squibb |
Renal Cell Carcinoma|Melanoma|Lung Cancer
|
August 16, 2016 | Phase 2 |
| NCT03991884 | University of Washington|Pfizer |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory B Lymphoblastic Lymphoma
|
September 24, 2019 | Phase 1 |
| NCT00004031 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group |
Lymphoma
|
July 1997 | Phase 3 |
| NCT01775475 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arkansas |
AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral+Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma
|
September 15, 2016 | Phase 2 |
| NCT03424733 | Holy Name Medical Center, Inc.|Biogen |
Multiple Sclerosis
|
September 25, 2017 | Phase 4 |
| NCT04497584 | University of Texas Southwestern Medical Center |
Advanced Squamous Non Small Cell Lung Cancer
|
August 4, 2021 | Phase 2 |
| NCT02129764 | Hebei Medical University |
Heart Failure, Hyperuricemia
|
December 2013 | Phase 2|Phase 3 |
| NCT04061772 | Zhejiang Cancer Hospital |
Peripheral T Cell Lymphoma
|
August 12, 2019 | Phase 2 |
| NCT02282683 | Hebei Medical University |
Heart Failure|Hyperuricemia
|
December 2013 | Phase 2|Phase 3 |
| NCT00910754 | Janssen Research & Development, LLC |
Prostate Neoplasms
|
May 2009 | Phase 1 |
| NCT01532856 | Grupo de Estudos Multicentricos em Onco-Hematologia |
Multiple Myeloma
|
January 2007 | Phase 3 |
| NCT04169100 | Narrows Institute for Biomedical Research|VA New York Harbor Healthcare System |
Long QT Syndrome|Connective Tissue Diseases|Rheumatoid Arthritis
|
September 28, 2011 | Phase 4 |
| NCT00550992 | Dutch Childhood Oncology Group|BFM Germany|CORS Monza Italy|Associazione Italiana Ematologia Oncologia Pediatrica|Australian and New Zealand Children´s Oncology Group|BFM Austria|CLCG France Belgium Portugal|COALL Germany|CPH, Czech republic|DFCI consortium USA|FRALLE France|Hong Kong|MD Anderson USA|NOPHO Scandinavian countries|PINDA, Chile|PPLLSG Poland|Seattle USA|SJCRH USA|UKCCSG United Kingdom |
Leukemia
|
January 2006 | Not Applicable |
| NCT00436956 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Prostate Cancer
|
October 16, 2006 | Phase 2 |
| NCT05008224 | Merck Sharp & Dohme LLC |
Classical Hodgkin Lymphoma
|
October 7, 2021 | Phase 2 |
| NCT01120470 | British Columbia Cancer Agency|Achieve Life Sciences |
Castration Resistant Prostate Cancer
|
September 2010 | Phase 2 |
| NCT00931918 | Millennium Pharmaceuticals, Inc.|Takeda |
Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
|
October 2009 | Phase 2 |
| NCT05457257 | AstraZeneca|Merck Sharp & Dohme LLC|Foundation Medicine, Inc.|Myriad Genetics, Inc. |
Metastatic Castration-resistant Prostate Cancer
|
July 29, 2022 | Phase 4 |
| NCT01969019 | Ruijin Hospital |
Graves´ Ophthalmopathy
|
January 2010 | Phase 4 |
| NCT00003541 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
June 1998 | Phase 1|Phase 2 |
| NCT00157014 | Astellas Pharma Inc|Astellas Pharma Canada, Inc. |
Heart Diseases|Heart Transplantation
|
May 10, 2004 | Phase 3 |
| NCT00430118 | University Hospital Schleswig-Holstein |
Leukemia
|
July 2000 | Phase 3 |
| NCT01576172 | National Cancer Institute (NCI) |
Castration-Resistant Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer AJCC v7
|
March 30, 2012 | Phase 2 |
| NCT02924766 | Janssen Research & Development, LLC |
Prostatic Neoplasms
|
October 3, 2016 | Phase 1 |
| NCT03984448 | National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Double-Expressor Lymphoma|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
|
August 7, 2019 | Phase 2|Phase 3 |
| NCT00929695 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Graft Versus Host Disease|Recurrent Adult Acute Lymphoblastic Leukemia
|
June 2009 | Phase 3 |
| NCT02991144 | Ultragenyx Pharmaceutical Inc |
Ornithine Transcarbamylase (OTC) Deficiency
|
January 2017 | Phase 1|Phase 2 |
| NCT04175431 | University of Washington|Blue Earth Diagnostics |
Prostate Adenocarcinoma|PSA Level Greater Than or Equal to 0.5|PSA Level Less Than Ten
|
September 30, 2020 | Phase 2 |
| NCT02596971 | Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
|
December 22, 2015 | Phase 1|Phase 2 |
| NCT01621386 | Hal C Charles|Merck Sharp & Dohme LLC|Duke University |
Asthma
|
January 2013 | Phase 1 |
| NCT04322357 | University of Florida|U.S. Army Medical Research and Development Command |
Duchenne Muscular Dystrophy (DMD)
|
July 30, 2020 | Phase 2 |
| NCT02463331 | University of Sao Paulo General Hospital |
Autoimmune Hepatitis
|
May 2003 | Phase 4 |
| NCT00842595 | French Innovative Leukemia Organisation |
Diffuse Large B-Cell Lymphoma
|
December 2003 | Phase 2 |
| NCT01925612 | Seagen Inc. |
Lymphoma, B-cell|Lymphoma, Large B-cell, Diffuse
|
August 2013 | Phase 2 |
| NCT01511536 | Sanofi |
Prostate Cancer
|
March 2012 | Phase 1|Phase 2 |
| NCT04702256 | Assistance Publique - Hôpitaux de Paris|Roche Pharma AG |
Lupus Nephritis|Systemic Lupus Erythematosus (SLE)
|
December 9, 2021 | Phase 3 |
| NCT03220022 | National Cancer Institute (NCI) |
AIDS-Related Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
|
November 3, 2017 | Phase 1 |
| NCT02807805 | Mamta Parikh|National Cancer Institute (NCI)|University of California, Davis |
Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer
|
October 2016 | Phase 2 |
| NCT00204737 | University of Wisconsin, Madison |
Post-traumatic Stress Disorder
|
December 2004 | Phase 4 |
| NCT00005584 | European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Study Association|UNICANCER |
Lymphoma
|
October 1998 | Phase 3 |
| NCT00388362 | Stanford University |
Graft vs Host Disease
|
November 2005 | Phase 2 |
| NCT04221477 | Hoffmann-La Roche |
Lupus Nephritis
|
August 10, 2020 | Phase 3 |
| NCT00379041 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma
|
September 1, 1993 | Phase 3 |
| NCT05024448 | University Hospital, Geneva |
Acute Peripheral Vestibulopathy
|
August 27, 2013 | Phase 4 |
| NCT00136565 | Lymphoma Study Association|Janssen-Cilag International NV |
Peripheral T-cell Lymphoma
|
January 8, 2006 | Phase 2 |
| NCT03861390 | University of North Carolina, Chapel Hill|United States Department of Defense |
Airway Inflammation
|
March 22, 2019 | Phase 1|Phase 2 |
| NCT02837965 | CHU de Reims |
Bullous Pemphigoid
|
April 2013 | |
| NCT02789878 | Instituto do Cancer do Estado de São Paulo|Janssen, LP |
Prostate Cancer
|
January 24, 2019 | Phase 2 |
| NCT00110006 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
December 2004 | Not Applicable |
| NCT00003650 | UNICANCER |
Lymphoma
|
February 1997 | Phase 3 |
| NCT00041210 | Mount Vernon Cancer Centre at Mount Vernon Hospital|National Cancer Institute (NCI) |
Lymphoma
|
October 2001 | Phase 3 |
| NCT00002657 | Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm
|
May 1995 | Phase 2 |
| NCT04884035 | Celgene |
Lymphoma, B-Cell
|
September 15, 2021 | Phase 1 |
| NCT02143414 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia
|
January 12, 2015 | Phase 2 |
| NCT04139304 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|Janssen Scientific Affairs, LLC|Montefiore Medical Center|Memorial Sloan Kettering Cancer Center|AIDS and Cancer Specimen Resource|The Emmes Company, LLC |
Plasmablastic Lymphoma|Ann Arbor Stage I Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
|
May 24, 2021 | Early Phase 1 |
| NCT03440515 | Asan Medical Center |
Gastrointestinal Stromal Tumor(GIST)
|
August 2014 | Phase 2 |
| NCT04780464 | European Organisation for Research and Treatment of Cancer - EORTC |
Advanced Soft-tissue Sarcoma
|
April 11, 2022 | Phase 3 |
| NCT02617485 | Mabion SA |
Diffuse Large B-Cell Lymphoma
|
December 2015 | Phase 3 |
| NCT02605694 | SecuraBio |
Lymphoma
|
December 2015 | Phase 2 |
| NCT01124838 | AbbVie (prior sponsor, Abbott)|AbbVie |
Uveitis
|
August 2010 | Phase 3 |
| NCT02237261 | University Hospital Heidelberg|German Cancer Research Center|Janssen-Cilag International NV|Mundipharma Research GmbH & Co KG|inVentiv Health Clinical |
Multiple Myeloma
|
November 2014 | Phase 2 |
| NCT01987076 | Assistance Publique - Hôpitaux de Paris |
Drug Rash With Eosinophilia and Systemic Symptoms
|
October 2013 | Not Applicable |
| NCT01695135 | Janssen Research & Development, LLC |
Prostate Neoplasms
|
August 9, 2012 | Phase 3 |
| NCT01251107 | Fondazione Michelangelo |
Hodgkin Lymphoma
|
March 2000 | Phase 3 |
| NCT00004436 | FDA Office of Orphan Products Development|Boston Children´s Hospital |
Hemangioma
|
July 1993 | Not Applicable |
| NCT00716066 | Fred Hutchinson Cancer Center |
Autoimmune Disease|Neurologic Autoimmune Disease|Autologous Transplant Autoimmune|Multiple Sclerosis Transplant|MS Stem Cell Transplant|Multiple Sclerosis Stem Cell Transplant|Stiff Person Syndrome|HCT for Neurologic Autoimmune Disorders|CIDP Transplant|Myasthenia Gravis Transplant|Autoimmune Nervous System Disorder|Central Nervous System Vasculitis|Cerebellar Degeneration|Chronic Inflammatory Demyelinating Polyneuropathy|Lambert Eaton Myasthenic Syndrome|Myasthenia Gravis|Neuromyelitis Optica|Opsoclonus Myoclonus Syndrome|Rasmussen Subacute Encephalitis
|
June 2008 | Phase 2 |
| NCT00006055 | Fairview University Medical Center|Office of Rare Diseases (ORD) |
Purpura, Schoenlein-Henoch|Graft Versus Host Disease|Anemia, Hemolytic, Autoimmune|Rheumatoid Arthritis|Churg-Strauss Syndrome|Hypersensitivity Vasculitis|Wegener´s Granulomatosis|Systemic Lupus Erythematosus|Giant Cell Arteritis|Pure Red Cell Aplasia|Juvenile Rheumatoid Arthritis|Polyarteritis Nodosa|Autoimmune Thrombocytopenic Purpura|Takayasu Arteritis
|
March 2000 | Not Applicable |
| NCT00025259 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma|Childhood Mixed Cellularity Classical Hodgkin Lymphoma|Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Childhood Nodular Sclerosis Classical Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma
|
September 2002 | Phase 3 |
| NCT00416832 | Christine Mauz-Körholz|Martin-Luther-Universität Halle-Wittenberg |
Lymphoma
|
November 2002 | Phase 2 |
| NCT00003910 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
July 16, 1999 | Phase 2 |
| NCT00440219 | Samuel Lunenfeld Research Institute, Mount Sinai Hospital |
Nasal Polyps
|
November 2010 | Phase 3 |
| NCT00024167 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Prostate Cancer
|
April 2002 | Phase 3 |
| NCT01040871 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Diffuse Large B-Cell Lymphoma
|
January 2010 | Phase 2 |
| NCT00885820 | Astellas Pharma Inc|Astellas Pharma Canada, Inc. |
Kidney Transplantation
|
September 2001 | Phase 4 |
| NCT00313781 | Pfizer |
Prostatic Neoplasms
|
May 2006 | Phase 2 |
| NCT00308113 | Cooperative International Neuromuscular Research Group|United States Department of Defense |
Duchenne Muscular Dystrophy
|
April 2007 | Phase 3 |
| NCT00203047 | Teva Branded Pharmaceutical Products R&D, Inc. |
Relapsing Remitting Multiple Sclerosis
|
January 2005 | Phase 4 |
| NCT01671423 | Albert Einstein Healthcare Network |
Cellulitis
|
August 2012 | Not Applicable |
| NCT02419469 | M.D. Anderson Cancer Center|Jazz Pharmaceuticals |
Leukemia|Precursor-B Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Lymphoma
|
November 13, 2015 | Phase 2 |
| NCT01540812 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
February 2012 | |
| NCT04291664 | DisperSol Technologies, LLC|Translational Drug Development |
Prostate Cancer
|
January 31, 2020 | Phase 1 |
| NCT02216747 | Rabin Medical Center |
Glomerular Disease
|
September 2014 | Phase 4 |
| NCT01523977 | Dana-Farber Cancer Institute|Novartis |
Acute Lymphoblastic Leukemia
|
November 2011 | Phase 1 |
| NCT05026229 | First Affiliated Hospital Xi´an Jiaotong University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Philadelphia-Positive Acute Lymphoblastic Leukemia|ALL, Adult
|
September 6, 2021 | Not Applicable |
| NCT00531791 | Laval University|GlaxoSmithKline |
Chronic Obstructive Pulmonary Disease (COPD)
|
November 2007 | Phase 3 |
| NCT00268593 | Progen Pharmaceuticals|Northern Sydney and Central Coast Area Health Service|Aventis Pharmaceuticals |
Prostate Cancer
|
August 2005 | Phase 2 |
| NCT00075725 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
December 29, 2003 | Phase 3 |
| NCT01208766 | Stichting Hemato-Oncologie voor Volwassenen Nederland|European Myeloma Network|Gruppo Italiano Malattie EMatologiche dell´Adulto|DSMM (Deutsche Studiengruppe Multiples Myelom)|NMSG (Nordic Myeloma Study Group)|Central European Myeloma Study Group |
Multiple Myeloma
|
January 2011 | Phase 3 |
| NCT04569032 | Seagen Inc. |
Peripheral T-cell Lymphoma
|
November 12, 2020 | Phase 2 |
| NCT00436839 | Sanofi |
Prostatic Neoplasms
|
January 2007 | Phase 3 |
| NCT03864250 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
Tacrolimus|Idiopathic Membranous Nephropathy|Clinical Trial
|
November 26, 2018 | Not Applicable |
| NCT01451710 | Nanjing University School of Medicine |
IgA Nephropathy
|
March 2011 | Not Applicable |
| NCT04072822 | Indiana University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
Alcoholic Hepatitis
|
July 10, 2020 | Phase 2 |
| NCT01829958 | Memorial Sloan Kettering Cancer Center |
Non Hodgkin Lymphoma (NHL)|Diffuse Large B-cell Lymphoma (DLBCL)
|
April 2013 | Not Applicable |
| NCT01718353 | Sanofi |
Prostate Cancer Metastatic
|
March 2013 | Phase 2 |
| NCT00089609 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Prostatic Neoplasms
|
April 19, 2005 | Phase 2 |
| NCT02257736 | Aragon Pharmaceuticals, Inc. |
Prostatic Neoplasms
|
November 26, 2014 | Phase 3 |
| NCT01375140 | M.D. Anderson Cancer Center|Incyte Corporation |
Myeloproliferative Diseases
|
September 22, 2011 | Phase 2 |
| NCT00060385 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma
|
March 2003 | Phase 2|Phase 3 |
| NCT03892785 | Centre Hospitalier Universitaire Dijon |
Giant Cell Arteritis
|
January 27, 2020 | Phase 3 |
| NCT01855750 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Lymphoma
|
September 3, 2013 | Phase 3 |
| NCT02343536 | Celgene |
Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular
|
April 29, 2015 | Phase 1 |
| NCT00019409 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Leukemia
|
October 1999 | Phase 3 |
| NCT02903160 | Icahn School of Medicine at Mount Sinai|Sanofi|Bayer |
Prostate Cancer
|
January 13, 2017 | Phase 2 |
| NCT04356430 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Prostate Cancer
|
April 1, 2019 | Phase 2 |
| NCT01676415 | Northwestern University |
Chronic Rhinosinusitis Without Nasal Polyps
|
August 2012 | Phase 4 |
| NCT02872584 | Rambam Health Care Campus |
Glucocorticoid
|
September 2016 | |
| NCT03595917 | Marlise R. Luskin|Novartis|Dana-Farber Cancer Institute |
B-cell Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph&addition; ALL
|
July 24, 2018 | Phase 1 |
| NCT00275535 | Mayo Clinic|Wyeth is now a wholly owned subsidiary of Pfizer|Genzyme, a Sanofi Company|Roche Pharma AG |
Kidney Diseases
|
April 2001 | Phase 4 |
| NCT03834519 | Merck Sharp & Dohme LLC |
Prostatic Neoplasms
|
May 2, 2019 | Phase 3 |
| NCT01889069 | Hoffmann-La Roche |
Lymphoma
|
July 31, 2013 | Phase 3 |
| NCT02961257 | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie |
Prostate Cancer Metastatic
|
May 5, 2017 | Phase 3 |
| NCT02565680 | University Hospital, Toulouse |
Acute Urticaria
|
February 2012 | Phase 2|Phase 3 |
| NCT05005637 | Fakultas Kedokteran Universitas Indonesia |
Tuberculous Uveitis
|
July 27, 2021 | Phase 2 |
| NCT00002599 | Medical Research Council|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
September 1994 | Phase 3 |
| NCT03598725 | Beijing Children´s Hospital |
Hemophilia A With Inhibitor
|
January 1, 2016 | Phase 4 |
| NCT04824092 | MorphoSys AG |
Diffuse Large B-cell Lymphoma
|
May 11, 2021 | Phase 3 |
| NCT00410657 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor
|
July 2006 | Phase 2 |
| NCT02685267 | Prostate Cancer Clinical Trials Consortium|University of Chicago|Astellas Pharma Inc |
Prostate Cancer
|
February 2016 | Phase 2 |
| NCT02521064 | McMaster Children´s Hospital|Canadian Association of Gastroenterology |
Inflammatory Bowel Diseases
|
July 2015 | |
| NCT03225924 | The Lymphoma Academic Research Organisation |
DLBCL
|
July 26, 2017 | Phase 1|Phase 2 |
| NCT02626455 | Bayer |
Lymphoma, Non-Hodgkin
|
January 6, 2016 | Phase 3 |
| NCT04918524 | Qilu Hospital of Shandong University |
Connective Tissue Diseases|Pregnancy Related
|
September 11, 2018 | |
| NCT00670358 | Mayo Clinic|National Cancer Institute (NCI) |
Lymphoma
|
August 25, 2008 | Phase 1|Phase 2 |
| NCT03792256 | Children´s Oncology Group |
Leukemia, Lymphocytic|Lymphoblastic Lymphoma|T-cell Lymphoma|T-cell Leukemia|Recurrent Disease|Acute Leukemia
|
April 11, 2019 | Phase 1 |
| NCT00440349 | University of Parma |
Retroperitoneal Fibrosis
|
October 2000 | Phase 2 |
| NCT01002703 | University of Leipzig|Celgene Corporation|Mundipharma Pte Ltd.|Amgen |
Multiple Myeloma
|
September 2009 | Phase 1|Phase 2 |
| NCT03553537 | Southwest Hospital, China |
Peripheral T-cell Lymphoma
|
June 2018 | Phase 3 |
| NCT00003584 | University of New Mexico |
Kidney Cancer
|
July 1998 | Phase 2 |
| NCT00000921 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
August 1996 | Phase 2 |
| NCT01190787 | European Myeloma Network|Fondazione EMN Italy Onlus |
Multiple Myeloma
|
July 2010 | Phase 2 |
| NCT01314118 | Janssen Biotech, Inc. |
Prostate Cancer|Prostatic Neoplasm
|
May 4, 2011 | Phase 2 |
| NCT00503984 | University of Miami |
Prostate Cancer|Pain
|
May 2007 | Phase 1|Phase 2 |
| NCT02405676 | Children´s Cancer Group, China|Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China|Nanjing Children´s Hospital|West China Second University Hospital|Xiangya Hospital of Central South University|Qilu Hospital of Shandong University|Children´s Hospital Of Soochow University|Tianjin Medical University Cancer Institute and Hospital |
Mature B-cell Non-Hodgkin Lymphoma
|
January 2015 | Phase 2|Phase 3 |
| NCT00002565 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
May 25, 1994 | Phase 3 |
| NCT01225874 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 1999 | Not Applicable |
| NCT01478308 | New Mexico Cancer Care Alliance |
Prostate Cancer
|
June 2011 | Phase 2 |
| NCT00405756 | Celgene Corporation |
Newly Diagnosed Multiple Myeloma
|
January 2007 | Phase 3 |
| NCT02595242 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Diffuse Large B Cell Lymphoma
|
June 2015 | Phase 1 |
| NCT01925131 | Southwest Oncology Group|National Cancer Institute (NCI) |
Acute Leukemias of Ambiguous Lineage|B-cell Adult Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma
|
April 2014 | Phase 1 |
| NCT00049569 | National Cancer Institute (NCI) |
L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Non-T, Non-B Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia
|
January 2003 | Not Applicable |
| NCT00018954 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
October 1992 | Phase 2 |
| NCT00002665 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia|Neutropenia|Thrombocytopenia
|
July 1995 | Phase 2 |
| NCT02723994 | Incyte Corporation|Children´s Oncology Group |
Leukemia
|
September 30, 2016 | Phase 2 |
| NCT00369044 | Hebei Medical University |
Heart Failure, Congestive
|
October 2006 | Phase 2|Phase 3 |
| NCT03356912 | Consorzio Oncotech |
Prostate Cancer|Castration-resistant Prostate Cancer
|
November 22, 2017 | Phase 2 |
| NCT04054375 | Northwestern University |
Limb-girdle Muscular Dystrophy|Becker Muscular Dystrophy
|
July 1, 2019 | Phase 2 |
| NCT02531633 | GlaxoSmithKline |
Giant Cell Arteritis
|
October 16, 2015 | Phase 3 |
| NCT00361920 | National Jewish Health|Genentech, Inc. |
Asthma
|
August 2006 | Not Applicable |
| NCT05302271 | Weill Medical College of Cornell University|National Heart, Lung, and Blood Institute (NHLBI) |
Friedreich Ataxia|Cardiomyopathies|Cardiac Hypertrophy|Myocardial Fibrosis
|
February 22, 2022 | Phase 1 |
| NCT01342016 | Astellas Pharma Inc|Astellas Pharma China, Inc. |
Lupus Nephritis
|
April 2011 | Phase 3 |
| NCT00946270 | M.D. Anderson Cancer Center|Celgene |
Polycythemia Vera|Thrombocythemia
|
July 22, 2009 | Phase 2 |
| NCT03414034 | Cardiff Oncology |
Metastatic Castration-Resistant Prostate Cancer
|
June 18, 2018 | Phase 2 |
| NCT00689936 | Celgene |
Multiple Myeloma
|
August 21, 2008 | Phase 3 |
| NCT01193257 | Millennium Pharmaceuticals, Inc.|Takeda |
Prostate Cancer
|
November 15, 2010 | Phase 3 |
| NCT01393730 | Mary-Ellen Taplin, MD|Dana-Farber Cancer Institute |
Prostate Cancer
|
September 2011 | Phase 2 |
| NCT05270057 | Medical College of Wisconsin |
B-cell Lymphoma|Burkitt Lymphoma
|
December 2022 | Phase 1 |
| NCT05129033 | Shanghai Zhongshan Hospital |
Allergic Bronchopulmonary Aspergillosis
|
November 15, 2021 | Not Applicable |
| NCT03315052 | Montefiore Medical Center |
Acute Cellular Graft Rejection|Liver Transplant Rejection
|
January 2019 | Phase 4 |
| NCT00513188 | University of Miami |
Lymphoma
|
February 2007 | Not Applicable |
| NCT00486421 | Mayo Clinic|National Cancer Institute (NCI) |
Nonneoplastic Condition
|
January 2007 | Early Phase 1 |
| NCT04477512 | Washington University School of Medicine|Bristol-Myers Squibb|Exelixis |
Metastatic Hormone Refractory Prostate Cancer
|
February 19, 2021 | Phase 1 |
| NCT00576069 | Gelb, Arthur F., M.D. |
Asthma
|
October 2007 | |
| NCT00080847 | National Cancer Institute (NCI) |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
March 2004 | Phase 2 |
| NCT04296578 | Stanford University |
Prostate Cancer|Castrate Resistant Prostate Cancer
|
October 2020 | Phase 1 |
| NCT02149433 | Kamuzu University of Health Sciences |
Pneumonia, Pneumocystis Jerovici
|
May 2012 | Not Applicable |
| NCT00787527 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC |
Lymphoma
|
November 2008 | Phase 1|Phase 2 |
| NCT00040937 | Southwest Oncology Group|National Cancer Institute (NCI) |
Multiple Myeloma
|
June 2002 | Phase 2 |
| NCT04025593 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
July 17, 2019 | Phase 2 |
| NCT02877303 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma
|
November 1, 2016 | Phase 2 |
| NCT00244127 | Zeneus Pharma |
Aggressive Non-Hodgkin´s Lymphoma in the Elderly.
|
October 2002 | Phase 2 |
| NCT00000596 | National Heart, Lung, and Blood Institute (NHLBI) |
Lung Diseases|Pulmonary Fibrosis|Sarcoidosis
|
June 1978 | Phase 2 |
| NCT00004071 | Pfizer |
Prostate Cancer
|
August 1999 | Phase 2|Phase 3 |
| NCT01138657 | AbbVie (prior sponsor, Abbott)|AbbVie |
Uveitis
|
August 2010 | Phase 3 |
| NCT04534478 | Hospital Universitari Vall d´Hebron Research Institute |
COVID-19 Pneumonia
|
September 7, 2020 | Phase 4 |
| NCT01893658 | Mayo Clinic|Genentech, Inc. |
Acute Interstitial Nephritis
|
June 1, 2018 | Phase 2 |
| NCT02955147 | Massachusetts General Hospital |
Giant Cell Arteritis|Temporal Arteritis|Horton´s Disease
|
December 1, 2016 | Phase 1|Phase 2 |
| NCT03613428 | Sichuan University |
Acute T Cell Leukemia
|
December 1, 2018 | Phase 1|Phase 2 |
| NCT03269669 | National Cancer Institute (NCI) |
Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Recurrent Follicular Lymphoma|Refractory Follicular Lymphoma
|
August 10, 2017 | Phase 2 |
| NCT02029638 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Kidney Transplantation
|
January 7, 2014 | Phase 2 |
| NCT00003152 | European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Stichting Hemato-Oncologie voor Volwassenen Nederland |
Lymphoma
|
March 1997 | Phase 3 |
| NCT01156883 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Leukemia
|
April 2010 | Not Applicable |
| NCT04729114 | Propella Therapeutics |
Prostate Cancer|mCRPC|mCSPC
|
June 14, 2021 | Phase 1|Phase 2 |
| NCT04933617 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Burkitt Lymphoma|High-grade B-cell Lymphoma|T-cell+Histocyte-rich Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma (DLBCL)|Germinal Center B-cell Type (GCB)
|
March 24, 2022 | Phase 1 |
| NCT02809079 | Third Affiliated Hospital, Sun Yat-Sen University|Zhongshan Ophthalmic Center, Sun Yat-sen University|Southern Medical University, China |
Neuromyelitis Optica Spectrum Disorders|Mycophenolate Mofetil|Efficacy and Safety
|
January 2016 | Phase 4 |
| NCT00003343 | Pfizer |
Prostate Cancer
|
March 1998 | Phase 3 |
| NCT01393639 | Pfizer |
Rheumatoid Arthritis
|
September 2011 | Phase 2 |
| NCT02951728 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
October 2016 | Phase 1|Phase 2 |
| NCT00101010 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Ortho Biotech, Inc. |
Lymphoma
|
September 2005 | Phase 2 |
| NCT03335956 | Corcept Therapeutics |
Healthy
|
September 21, 2017 | Phase 1 |
| NCT00002590 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
July 1994 | Phase 2 |
| NCT01230983 | Children´s Oncology Group|National Cancer Institute (NCI) |
Cardiac Toxicity|Leukemia|Lymphoma
|
June 1996 | Phase 3 |
| NCT03600805 | Sanofi|Regeneron Pharmaceuticals |
Giant Cell Arteritis
|
November 20, 2018 | Phase 3 |
| NCT01683994 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Prostatic Neoplasms
|
September 7, 2012 | Phase 1|Phase 2 |
| NCT02205762 | North American Consortium for Histiocytosis|Histiocyte Society |
Langerhans Cell Histiocytosis
|
July 2014 | Phase 2|Phase 3 |
| NCT00118209 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Large B Cell Lymphoma
|
May 2005 | Phase 3 |
| NCT03141671 | Dana-Farber Cancer Institute|Janssen Pharmaceutica |
Prostate Cancer
|
November 24, 2017 | Phase 2 |
| NCT00365274 | National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma
|
August 2006 | Phase 2 |
| NCT02217566 | Janssen Research & Development, LLC |
Prostatic Neoplasms
|
September 23, 2014 | Phase 2 |
| NCT01524536 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Eosinophilia|Hypereosinophilic Syndrome|Leukocyte Disorder|Hematologic Diseases
|
February 16, 2012 | Phase 4 |
| NCT00836810 | University Hospitals Bristol and Weston NHS Foundation Trust |
Polymyalgia Rheumatica
|
October 2009 | Phase 2|Phase 3 |
| NCT00458848 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Leukemia
|
October 2004 | Phase 2 |
| NCT00295932 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|Columbia University|Emory University |
Leukemia|Lymphoma
|
December 13, 2005 | Phase 1|Phase 2 |
| NCT00900445 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia
|
March 24, 2008 | |
| NCT00540644 | Attaya Suvannasankha|Celgene|Indiana University |
Multiple Myeloma
|
October 2007 | Phase 2 |
| NCT01569204 | University of Cologne |
Hodgkin Lymphoma
|
October 2012 | Phase 2 |
| NCT01172639 | P. Verschueren|Agentschap voor Innovatie door Wetenschap en Technologie|Universitaire Ziekenhuizen KU Leuven |
Rheumatoid Arthritis
|
February 2009 | Phase 4 |
| NCT01009970 | Fondazione Italiana Linfomi ONLUS |
Diffuse Large B-Cell Lymphoma
|
May 2010 | Phase 2 |
| NCT00916123 | Weill Medical College of Cornell University |
Prostate Cancer
|
May 2009 | Phase 1 |
| NCT00052936 | German High-Grade Non-Hodgkin´s Lymphoma Study Group|Universität des Saarlandes |
Lymphoma
|
January 2001 | Phase 3 |
| NCT00132301 | VA Office of Research and Development|Sanofi |
Prostate Cancer
|
June 2006 | Phase 3 |
| NCT01746173 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center |
T-cell Non-Hodgkin Lymphoma
|
July 2013 | Phase 2 |
| NCT00002700 | European Organisation for Research and Treatment of Cancer - EORTC|Acute Leukemia French Association |
Leukemia|Lymphoma
|
August 1995 | Phase 3 |
| NCT00975078 | University Hospital, Basel, Switzerland |
Adrenal Gland Hypofunction
|
May 2009 | Phase 4 |
| NCT00049595 | European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Lymphoma Study Association|Grup per l´Estudi dels Limfomes de Catalunya i Balears|NCIC Clinical Trials Group|Australasian Leukaemia and Lymphoma Group|Nordic Lymphoma Group |
Lymphoma
|
August 2002 | Phase 3 |
| NCT02036060 | Spanish Oncology Genito-Urinary Group|Janssen, LP|Apices Soluciones S.L. |
Metastatic Prostate Cancer
|
February 7, 2014 | Phase 2 |
| NCT04844814 | Assistance Publique - Hôpitaux de Paris |
Gout|Chronic Kidney Disease|Renal Transplantation
|
June 2, 2022 | Phase 2 |
| NCT01088529 | Cougar Biotechnology, Inc. |
Prostate Cancer
|
December 2009 | Phase 2 |
| NCT02330952 | Assistance Publique - Hôpitaux de Paris |
Pulmonary Disease|Chronic Obstructive (MeSH)
|
February 10, 2015 | Phase 4 |
| NCT05605899 | Kite, A Gilead Company|Gilead Sciences |
High-risk Large B-cell Lymphoma (LBCL)
|
November 2022 | Phase 3 |
| NCT03758989 | University of Rochester |
DLBCL
|
May 8, 2019 | Phase 2 |
| NCT02776605 | PETHEMA Foundation |
ALL
|
June 2016 | Phase 2 |
| NCT00002463 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
February 1989 | Phase 2 |
| NCT01445535 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
T-Cell Peripheral Lymphoma|Gamma Delta Hepatosplenic T-Cell Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma|NK T-Cell Lymphoma
|
January 13, 2009 | Phase 1 |
| NCT03207815 | Gilead Sciences|Galapagos NV |
Noninfectious Uveitis
|
July 26, 2017 | Phase 2 |
| NCT05204927 | Curium US LLC |
Metastasis From Malignant Tumor of Prostate
|
February 14, 2022 | Phase 3 |
| NCT02702960 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Fibrolamellar Cancer Foundation |
Fibrolamellar Hepatocellular Carcinoma|Hepatocellular Carcinoma (Fibrolamellar Variant)|Hepatocellular Carcinoma
|
March 2016 | Phase 2 |
| NCT02702778 | Dinora, Inc.|Analgesic Solutions|PharPoint Research, Inc. |
Polymyalgia Rheumatica
|
February 2016 | Phase 2 |
| NCT03098836 | Daniel George, MD|Janssen Scientific Affairs, LLC|Duke University |
Prostate Cancer
|
July 10, 2017 | Phase 2 |
| NCT00774202 | Weill Medical College of Cornell University|Biogen|Genentech, Inc. |
Immune Thrombocytopenic Purpura
|
November 2003 | Phase 2|Phase 3 |
| NCT04216524 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Blastic Plasmacytoid Dendritic Cell Neoplasm
|
May 29, 2020 | Phase 2 |
| NCT03338790 | Bristol-Myers Squibb|Clovis Oncology, Inc.|Astellas Pharma Inc |
Prostate Cancer
|
December 19, 2017 | Phase 2 |
| NCT01199029 | Pfizer |
Healthy
|
August 2010 | Phase 1 |
| NCT04734730 | City of Hope Medical Center|National Cancer Institute (NCI) |
Castration-Sensitive Prostate Carcinoma|Metastatic Prostate Adenocarcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8
|
May 4, 2021 | Phase 2 |
| NCT05276492 | University of Chicago |
Prostate Cancer|Prostate Adenocarcinoma|Prostate Neoplasm|Prostate Cancer Metastatic
|
June 1, 2022 | Phase 1 |
| NCT02734771 | Patrick Reagan|Seagen Inc.|University of Rochester |
Diffuse Large B-Cell Lymphoma
|
June 2016 | Phase 2 |
| NCT00004228 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
June 2000 | Phase 3 |
| NCT01132807 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
May 2010 | Phase 2 |
| NCT02532777 | Nanjing Children´s Hospital |
Henoch-Schoenlein Purpura Nephritis
|
August 2015 | Phase 2 |
| NCT03742297 | PETHEMA Foundation |
Newly Diagnosed Multiple Myeloma
|
October 22, 2018 | Phase 3 |
| NCT00000421 | NYU Langone Health|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Systemic Lupus Erythematosus
|
September 1997 | Phase 2 |
| NCT00995722 | Michael Benatar|University of Miami|University of Rochester |
Ocular Myasthenia Gravis
|
December 2011 | Phase 3 |
| NCT00006669 | Medstar Health Research Institute |
Lymphoma
|
September 1999 | Phase 2 |
| NCT02815059 | University of Utah|Janssen, LP |
Acute Lymphoblastic Leukemia
|
September 28, 2016 | Phase 1 |
| NCT00000178 | National Institute on Aging (NIA) |
Alzheimer Disease
|
Phase 3 | |
| NCT05479448 | University Hospital, Basel, Switzerland|Schweizerische Stiftung für die Erforschung der Muskelkrankheiten|Novartis |
Polymyalgia Rheumatica (PMR)|Giant Cell Arteritis (GCA)
|
June 3, 2022 | |
| NCT02162771 | Celltrion |
Lymphoma, Follicular
|
July 14, 2014 | Phase 3 |
| NCT00657774 | SkyePharma AG|Abbott |
Asthma
|
April 2008 | Phase 1 |
| NCT00107198 | Children´s Oncology Group|National Cancer Institute (NCI) |
Ann Arbor Stage I Childhood Hodgkin Lymphoma|Ann Arbor Stage II Childhood Hodgkin Lymphoma|Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
|
January 2, 2006 | Phase 2 |
| NCT00634933 | Pfizer|Trubion Pharmaceuticals+Emergent BioSolutions Inc. |
Arthritis, Rheumatoid
|
March 2008 | Phase 2 |
| NCT00033293 | Children´s Oncology Group|National Cancer Institute (NCI) |
Disseminated Neuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma
|
March 15, 2004 | Phase 3 |
| NCT00002757 | Children´s Oncology Group|National Cancer Institute (NCI)|Societe Francaise Oncologie Pediatrique|Children´s Cancer and Leukaemia Group |
Leukemia|Lymphoma
|
June 2001 | Phase 3 |
| NCT05578456 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Ningbo Women & Children´s Hospital|Jinhua People´s Hospital|Jiaxing Maternity and Child Health Care Hospital |
Thyroiditis, Autoimmune|Infertility
|
November 1, 2022 | Phase 4 |
| NCT02494921 | Rahul Aggarwal|Novartis|University of California, San Francisco |
Prostate Cancer
|
November 20, 2015 | Phase 1|Phase 2 |
| NCT03128905 | Lille Catholic University|University Hospital, Lille|Hopital Lariboisière|Bichat Hospital|Valenciennes Hospital Centre|Armentières Hospital Centre|Dunkerque Hospital Centre |
Chondrocalcinosis
|
February 5, 2018 | Phase 3 |
| NCT01083615 | Achieve Life Sciences|Teva Pharmaceuticals USA |
Castrate-Resistant Prostate Cancer|Hormone Refractory Prostate Cancer
|
March 2010 | Phase 3 |
| NCT02960022 | Astellas Pharma Global Development, Inc.|Pfizer|Astellas Pharma Inc |
Prostate Cancer
|
December 22, 2016 | Phase 2 |
| NCT05006664 | Czech Lymphoma Study Group |
Lymphoma, T-Cell, Peripheral
|
October 2021 | Phase 2 |
| NCT03903835 | Karolinska Institutet|The Swedish Research Council|Kom Op Tegen Kanker|Janssen Pharmaceutica N.V., Belgium |
Metastatic Castration-resistant Prostate Cancer|Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
|
February 1, 2019 | Phase 3 |
| NCT04220632 | Innovent Biologics (Suzhou) Co. Ltd. |
GVHD,Acute
|
June 18, 2020 | Phase 1|Phase 2 |
| NCT00466843 | Office of Rare Diseases (ORD)|Rare Diseases Clinical Research Network |
Myelodysplastic Syndrome
|
April 2007 | Phase 2 |
| NCT01279694 | Nantes University Hospital |
Myeloma
|
October 2010 | Phase 1|Phase 2 |
| NCT00301821 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
January 2006 | Phase 2 |
| NCT00107380 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
November 2005 | Phase 2 |
| NCT00417079 | Sanofi |
Neoplasms|Prostatic Neoplasms
|
January 2007 | Phase 3 |
| NCT01814865 | British Columbia Cancer Agency|Janssen Research & Development, LLC |
Post-menopausal ER&addition; Stage I-IIIA Primary Operable Breast Cancer
|
May 2013 | Phase 2 |
| NCT04872790 | OHSU Knight Cancer Institute|AbbVie|Oregon Health and Science University |
B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Recurrent B Acute Lymphoblastic Leukemia
|
October 2, 2022 | Phase 1 |
| NCT04056754 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Metastatic Castration Resistant Prostate Cancer
|
July 16, 2014 | Phase 3 |
| NCT01994590 | M.D. Anderson Cancer Center|Novartis |
Prostate Cancer
|
May 19, 2014 | Phase 2 |
| NCT00717379 | Astellas Pharma Inc |
Kidney Transplantation|Kidney Failure, Chronic|Renal Insufficiency, Chronic
|
May 2007 | Phase 4 |
| NCT04267887 | OHSU Knight Cancer Institute|Janssen Scientific Affairs, LLC|Oregon Health and Science University |
Castration-Sensitive Prostate Carcinoma|Metastatic Prostate Carcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8
|
May 11, 2020 | Phase 2 |
| NCT04406376 | Carmel Medical Center |
Bell Palsy
|
May 12, 2020 | Phase 4 |
| NCT02910245 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|ZonMw: The Netherlands Organisation for Health Research and Development |
Colitis, Ulcerative
|
November 2016 | Phase 3 |
| NCT00707759 | Fondo Nacional de Desarrollo Científico y Tecnológico, Chile |
Kidney Diseases
|
June 2008 | Phase 3 |
| NCT04529772 | Acerta Pharma BV|AstraZeneca |
Diffuse Large B-Cell Lymphoma
|
October 8, 2020 | Phase 3 |
| NCT00423098 | Novartis Pharmaceuticals|Novartis |
Lupus Nephritis
|
February 2007 | Phase 2 |
| NCT05444946 | Postgraduate Institute of Medical Education and Research |
Chronic Pulmonary Aspergillosis|Allergic Bronchopulmonary Aspergillosis
|
June 15, 2022 | Not Applicable |
| NCT02911142 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Primary Effusion Lymphoma|B-Cell Neoplasm
|
July 3, 2017 | Phase 1|Phase 2 |
| NCT00626678 | Tehran University of Medical Sciences |
Pemphigus Vulgaris
|
January 2008 | Phase 2 |
| NCT00764907 | University Hospital, Motol|National Cancer Institute (NCI) |
Leukemia
|
November 2002 | Phase 3 |
| NCT00043147 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Graft Versus Host Disease
|
April 2002 | Phase 3 |
| NCT04833907 | Myrtelle Inc. |
Canavan Disease
|
April 1, 2021 | Phase 1|Phase 2 |
| NCT04408625 | Prevail Therapeutics|Eli Lilly and Company |
Frontotemporal Dementia
|
November 9, 2020 | Phase 1|Phase 2 |
| NCT00877006 | Teva Branded Pharmaceutical Products R&D, Inc. |
Non-Hodgkin´s Lymphoma|Mantle Cell Lymphoma
|
April 30, 2009 | Phase 3 |
| NCT02909335 | Rennes University Hospital |
Liver Transplantation
|
November 2016 | Phase 3 |
| NCT01924286 | University of Cape Town|Institute of Tropical Medicine, Belgium|Imperial College London|European and Developing Countries Clinical Trials Partnership (EDCTP)|Department of Science and Technology, South Africa |
Immune Reconstitution Inflammatory Syndrome|HIV|Tuberculosis
|
August 30, 2013 | Phase 3 |
| NCT02712697 | Shanghai University of Traditional Chinese Medicine|RenJi Hospital|Ruijin Hospital|Shanghai 6th People´s Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Fudan University |
Primary IgA Nephropathy
|
June 2016 | Not Applicable |
| NCT01026220 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma
|
December 7, 2009 | Phase 3 |
| NCT05157971 | City of Hope Medical Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|Ph-Like Acute Lymphoblastic Leukemia
|
March 17, 2022 | Phase 1 |
| NCT04469842 | Vanderbilt University Medical Center|Veloxis Pharmaceuticals |
Lung Transplant; Complications
|
October 1, 2022 | Early Phase 1 |
| NCT02386735 | Prof. Dr. Jörg Leuppi|Institut für Hausarztmedizin Basel|Kantonsspital Baselland Bruderholz|Cantonal Hosptal, Baselland |
Pulmonary Disease, Chronic Obstructive|Adverse Effect of Glucocorticoids and Synthetic Analogues|Disease Exacerbation
|
March 2015 | Not Applicable |
| NCT03043105 | Peking Union Medical College Hospital |
Multicentric Castleman Disease
|
January 1, 2017 | Phase 2 |
| NCT02499887 | State University of New York at Buffalo |
Asthma|COPD
|
January 2016 | Not Applicable |
| NCT00348816 | The University of Texas Health Science Center at San Antonio |
Prostate Cancer
|
May 2006 | Phase 2 |
| NCT04262154 | Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Stand Up To Cancer |
Metastatic Prostate Cancer
|
March 3, 2020 | Phase 2 |
| NCT00054665 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
B-Cell Lymphoma
|
February 2003 | Phase 2 |
| NCT00744497 | Bristol-Myers Squibb |
Prostatic Neoplasms
|
October 2008 | Phase 3 |
| NCT00137969 | Genentech, Inc. |
Lupus Erythematosus, Systemic
|
May 10, 2005 | Phase 2|Phase 3 |
| NCT04484506 | Peking University|Peking University Cancer Hospital & Institute|Peking University International Hospital|Hebei Medical University Fourth Hospital|Jiangxi Provincial Cancer Hospital |
NK+T Cell Lymphoma Nos
|
October 20, 2011 | Phase 2 |
| NCT02003222 | National Cancer Institute (NCI)|Canadian Cancer Trials Group |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
December 23, 2013 | Phase 3 |
| NCT00501826 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma
|
July 11, 2007 | Phase 2 |
| NCT04598477 | argenx |
Pemphigus Vulgaris|Pemphigus Foliaceus
|
July 15, 2021 | Phase 3 |
| NCT02752815 | Ruijin Hospital |
Diffuse Large B-cell Lymphoma
|
April 2016 | Phase 4 |
| NCT04835870 | The First Affiliated Hospital of Soochow University |
Non-GCB+ABC Diffuse Large B-Cell Lymphoma
|
April 1, 2021 | Phase 2 |
| NCT01559727 | Hebei Medical University |
Heart Failure
|
March 2012 | Phase 3 |
| NCT03920007 | Atsena Therapeutics Inc. |
Leber Congenital Amaurosis|LCA|LCA1
|
September 12, 2019 | Phase 1|Phase 2 |
| NCT01331018 | Fred Hutchinson Cancer Center|National Heart, Lung, and Blood Institute (NHLBI)|Rocket Pharma Limited |
Fanconi Anemia
|
February 22, 2012 | Phase 1 |
| NCT00039351 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma
|
March 2002 | Phase 2 |
| NCT01157975 | University of California, San Diego |
Hepatitis C
|
October 2008 | Phase 2 |
| NCT04745949 | M.D. Anderson Cancer Center |
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
|
May 10, 2021 | Phase 2 |
| NCT04530565 | National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
|
October 14, 2020 | Phase 3 |
| NCT01352338 | UMC Utrecht|Celgene Corporation |
Multiple Myeloma
|
August 2011 | Phase 1|Phase 2 |
| NCT04799275 | National Cancer Institute (NCI) |
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Grade 3b Follicular Lymphoma|HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Intravascular Large B-Cell Lymphoma|Lymphoplasmacytic Lymphoma|Nodular Lymphocyte Predominant Hodgkin Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
|
March 19, 2021 | Phase 2|Phase 3 |
| NCT04782700 | Northwell Health |
Covid19|Lung Inflammation|Hypoxemic Respiratory Failure
|
April 1, 2021 | Not Applicable |
| NCT00278278 | Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
September 2003 | Phase 3 |
| NCT01995513 | Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc. |
Prostate Cancer
|
October 22, 2013 | Phase 4 |
| NCT00023244 | National Institute of Allergy and Infectious Diseases (NIAID)|Cooperative Clinical Trials in Pediatric Transplantation |
End-Stage Renal Disease
|
January 2001 | Phase 2 |
| NCT01649635 | Sanofi |
Prostate Cancer
|
July 2012 | Phase 4 |
| NCT02858804 | Institute of Hematology & Blood Diseases Hospital |
Mantle Cell Lymphoma
|
January 2016 | Phase 4 |
| NCT00135499 | Lymphoma Study Association|Fondation ARC |
Lymphoma, Large-Cell, Diffuse
|
October 16, 2001 | Phase 3 |
| NCT00005089 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 2000 | Phase 2 |
| NCT00002678 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Multiple Myeloma and Plasma Cell Neoplasm
|
June 2, 1995 | Phase 3 |
| NCT04869488 | Jiangsu HengRui Medicine Co., Ltd. |
Metastatic Castration Resistant Prostate Cancer
|
July 26, 2021 | Phase 2 |
| NCT00588406 | Northwell Health|AstraZeneca|Jacobi Medical Center|Nassau University Medical Center |
Asthma
|
September 2007 | Phase 3 |
| NCT04652414 | Vanderbilt University Medical Center |
Community-acquired Pneumonia|Cognition Disorder
|
December 1, 2020 | Phase 2 |
| NCT01821040 | Mundipharma Research Limited |
Polymyalgia Rheumatica
|
March 2013 | Phase 3 |
| NCT00801281 | Polish Lymphoma Research Group |
Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma
|
February 2007 | Phase 3 |
| NCT00544219 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
September 2007 | Not Applicable |
| NCT01711827 | Astellas Pharma Global Development, Inc.|Basilea Pharmaceutica International Ltd|Astellas Pharma Inc |
Healthy Subjects|Pharmacokinetics of Isavuconazole|Pharmacokinetics of Prednisolone
|
February 2012 | Phase 1 |
| NCT02558517 | Groupe Hospitalier Pitie-Salpetriere |
Systemic Lupus Erythematosus
|
January 2014 | Phase 3 |
| NCT05267600 | argenx |
Bullous Pemphigoid
|
June 9, 2022 | Phase 2|Phase 3 |
| NCT00035958 | Children´s Hospital Medical Center, Cincinnati|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Immunex Corporation |
Dermatomyositis
|
August 2002 | Phase 2|Phase 3 |
| NCT02284464 | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|Sociedad Andaluza de Trasplantes de Organos y Tejidos |
Other Complication of Kidney Transplant|Renal Transplant Rejection
|
February 2015 | Phase 4 |
| NCT05459649 | Peking University People´s Hospital |
Immune Thrombocytopenia
|
July 20, 2022 | Phase 2 |
| NCT02660762 | Sun Yat-sen University |
Leukaemia,Lymphoblastic
|
January 2016 | Phase 2 |
| NCT01274403 | Gruppo Italiano Studio Linfomi |
Multiple Myeloma
|
Phase 2 | |
| NCT01334502 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
March 2012 | Phase 1 |
| NCT00693524 | Astellas Pharma Inc |
Liver Transplantation
|
November 2002 | Phase 2 |
| NCT00184002 | University of Southern California|Ortho Biotech, Inc. |
Non-Hodgkin´s Lymphoma
|
January 10, 2003 | Phase 2 |
| NCT03764540 | Centre hospitalier de l´Université de Montréal (CHUM)|Genzyme, a Sanofi Company |
Metastatic Prostate Cancer
|
April 1, 2019 | Phase 2 |
| NCT03117751 | St. Jude Children´s Research Hospital|Incyte Corporation|Amgen|Servier |
Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma
|
March 29, 2017 | Phase 2|Phase 3 |
| NCT02496585 | Memorial Sloan Kettering Cancer Center|Boehringer Ingelheim |
Lung Cancer|Lung Metastases
|
July 2015 | Phase 2 |
| NCT00841802 | Northwestern University|National Heart, Lung, and Blood Institute (NHLBI) |
Chronic Sinusitis|Rhinosinusitis|Nasal Polyps
|
July 2008 | Phase 4 |
| NCT03290456 | Hospices Civils de Lyon |
Granulomatosis With Polyangitis
|
August 20, 2019 | Not Applicable |
| NCT00031824 | Children´s Oncology Group|National Cancer Institute (NCI) |
Graft Versus Host Disease
|
April 2002 | Phase 3 |
| NCT02457221 | Astellas Pharma China, Inc.|Astellas Pharma Inc |
Lupus Nephritis
|
March 10, 2015 | Phase 3 |
| NCT02556866 | Assistance Publique - Hôpitaux de Paris |
Cryoglobulinemia|Systemic Vasculitis
|
July 17, 2015 | Phase 2 |
| NCT03827018 | Kiniksa Pharmaceuticals, Ltd. |
Giant Cell Arteritis
|
September 20, 2018 | Phase 2 |
| NCT03388008 | Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)|Bristol-Myers Squibb |
Lung Transplant Rejection|Antibody-mediated Rejection
|
December 17, 2019 | Phase 2 |
| NCT01995058 | Exelixis |
Prostate Cancer|Castration Resistant Prostate Cancer|Prostatic Neoplasms
|
December 2013 | Phase 2 |
| NCT01978665 | Bispebjerg Hospital |
Exercise Performance in Copd Patients
|
April 2013 | Phase 4 |
| NCT02106468 | October 6 University |
Oral Lichen Planus
|
May 2013 | Phase 2 |
| NCT03007732 | Lawrence Fong|Prostate Cancer Foundation|Merck Sharp & Dohme LLC|Dynavax Technologies Corporation|University of California, San Francisco |
Prostatic Neoplasms
|
May 17, 2017 | Phase 2 |
| NCT03952572 | Peking University |
Peripheral T-cell Lymphoma
|
May 10, 2019 | Phase 3 |
| NCT04344288 | Hospices Civils de Lyon |
Viral Pneumonia Human Coronavirus|COVID-19
|
April 21, 2020 | Phase 2 |
| NCT01792687 | Aragon Pharmaceuticals, Inc. |
Prostate Cancer
|
February 5, 2013 | Phase 1 |
| NCT00597064 | Federal University of São Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo |
Asthma
|
July 2006 | Phase 4 |
| NCT02190994 | West China Hospital |
Pituitary Neoplasms|Craniopharyngiomas
|
August 2013 | Phase 4 |
| NCT00304018 | University of California, San Francisco|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
October 2002 | Phase 1 |
| NCT02985957 | Bristol-Myers Squibb |
Prostate Cancer
|
March 26, 2017 | Phase 2 |
| NCT03412565 | Janssen Research & Development, LLC |
Multiple Myeloma
|
April 26, 2018 | Phase 2 |
| NCT04323956 | Mayo Clinic|National Cancer Institute (NCI) |
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Follicular Lymphoma|Ann Arbor Stage II Marginal Zone Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Follicular Lymphoma|Ann Arbor Stage III Marginal Zone Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Follicular Lymphoma|Ann Arbor Stage IV Marginal Zone Lymphoma|Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Indolent Non-Hodgkin Lymphoma
|
June 15, 2020 | Phase 1 |
| NCT00032019 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
February 2002 | Phase 2 |
| NCT04569890 | RenJi Hospital |
Rheumatoid Arthritis|Pregnancy Related
|
December 1, 2020 | Not Applicable |
| NCT00331344 | National Cancer Institute (NCI) |
Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage IV Prostate Cancer
|
April 2006 | Phase 1|Phase 2 |
| NCT00527124 | National Cancer Institute (NCI) |
Adenocarcinoma of the Prostate|Stage IV Prostate Cancer
|
November 2007 | Phase 2 |
| NCT03549663 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
Idiopathic Membranous Nephropathy
|
July 4, 2018 | Not Applicable |
| NCT00004010 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 2 |
| NCT02406092 | Hoffmann-La Roche |
Non-Hodgkin Lymphoma
|
October 13, 2015 | Phase 3 |
| NCT00070447 | National Cancer Institute (NCI) |
Lymphoma
|
November 2003 | Phase 2 |
| NCT03070522 | The Hospital for Sick Children|Canadian Cystic Fibrosis Foundation |
Cystic Fibrosis Pulmonary Exacerbation
|
May 1, 2017 | Phase 3 |
| NCT00574496 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
November 13, 2007 | Phase 2 |
| NCT01358253 | Ruijin Hospital |
Acute Lymphoblastic Leukemia
|
December 2010 | Phase 4 |
| NCT00121199 | National Cancer Institute (NCI) |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
June 2005 | Phase 2 |
| NCT01921218 | Andrew B Adams|Bristol-Myers Squibb|Emory University |
Failing Renal Allograft
|
August 2013 | Phase 3 |
| NCT04803201 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Follicular T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Peripheral T-Cell Lymphoma, Not Otherwise Specified
|
July 30, 2021 | Phase 2 |
| NCT03009981 | Alliance Foundation Trials, LLC.|Janssen Research & Development, LLC |
Prostate Cancer
|
March 6, 2017 | Phase 3 |
| NCT02953678 | Incyte Corporation |
Graft-versus-host Disease (GVHD)
|
December 30, 2016 | Phase 2 |
| NCT02627417 | Assistance Publique - Hôpitaux de Paris |
Adult Immune Thrombocytopenia (ITP)|Dapsone
|
December 2015 | Phase 3 |
| NCT01084655 | Millennium Pharmaceuticals, Inc.|Takeda |
Prostate Cancer
|
July 2010 | Phase 1|Phase 2 |
| NCT03150056 | GlaxoSmithKline |
Solid Tumours
|
July 18, 2017 | Phase 1 |
| NCT02495077 | National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation|Rho Federal Systems Division, Inc. |
Kidney Transplant
|
November 2, 2015 | Phase 2 |
| NCT00416143 | Sheba Medical Center |
Sudden Loss of Hearing
|
June 2006 | Phase 2|Phase 3 |
| NCT00633919 | ALK-Abelló A+S |
Allergy
|
July 2006 | Phase 2|Phase 3 |
| NCT03222687 | Shandong University |
Henoch-Schönlein Purpura Nephritis
|
September 1, 2015 | Phase 4 |
| NCT02055820 | Hoffmann-La Roche|AbbVie |
Lymphoma, Non-Hodgkin
|
November 17, 2013 | Phase 1|Phase 2 |
| NCT01848067 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Millennium: The Takeda Oncology Company|Thomas Jefferson University |
Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer
|
August 14, 2013 | Phase 1|Phase 2 |
| NCT00411528 | Novartis Pharmaceuticals|Novartis |
Metastatic Hormone Refractory Prostate Cancer
|
September 2006 | Phase 2 |
| NCT01432080 | Maisonneuve-Rosemont Hospital|The Canadian Blood and Marrow Transplant Group |
Respiratory Tract Infections|Bronchiolitis Obliterans|Cryptogenic Organizing Pneumonia|Lung Diseases, Interstitial
|
September 2011 | Phase 2 |
| NCT01527422 | Fernando Cabanillas|Genzyme, a Sanofi Company|Auxilio Mutuo Cancer Center |
Lymphoma|Non Hodgkin´s Lymphoma
|
January 2006 | Phase 1|Phase 2 |
| NCT00004646 | National Center for Research Resources (NCRR)|National Institute of Neurological Disorders and Stroke (NINDS)|University of Rochester|Office of Rare Diseases (ORD) |
Duchenne Muscular Dystrophy
|
April 1995 | Phase 3 |
| NCT00416533 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Prostate Cancer
|
August 2004 | Phase 2 |
| NCT05303792 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma
|
February 2023 | Phase 2 |
| NCT01877746 | St. Anne´s University Hospital Brno, Czech Republic |
Inflammatory Cardiomyopathy
|
January 2013 | Phase 3 |
| NCT03283202 | Celgene |
Diffuse B-Cell Lymphoma
|
October 4, 2017 | Phase 1 |
| NCT00352794 | M.D. Anderson Cancer Center|Celgene Corporation |
Myelofibrosis
|
July 7, 2006 | Phase 2 |
| NCT00378443 | Peking University |
Glomerulonephritis, IGA
|
January 2006 | Not Applicable |
| NCT00004197 | University of Nebraska|National Cancer Institute (NCI) |
Lymphoma
|
June 1999 | Phase 2 |
| NCT02614612 | Incyte Corporation |
Graft-versus-host Disease (GVHD)
|
December 2015 | Phase 1 |
| NCT03023046 | University of Washington|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
February 23, 2017 | Phase 2 |
| NCT00324467 | British Columbia Cancer Agency|Hoffmann-La Roche |
Lymphoma, Non-Hodgkin|Advanced Stage Diffuse Large B-Cell Non-Hodgkin´s Lymphoma
|
August 2006 | Phase 2 |
| NCT00079261 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma|Small Intestine Cancer
|
January 2004 | Phase 2 |
| NCT01522443 | Exelixis |
Prostate Cancer|Castration Resistant Prostate Cancer|Pain|Prostatic Neoplasms
|
March 2012 | Phase 3 |
| NCT00288626 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Relapsing-Remitting Multiple Sclerosis
|
July 2006 | Phase 2 |
| NCT00514267 | Astellas Pharma Inc |
Prostate Cancer|Tumors
|
May 2007 | Phase 1|Phase 2 |
| NCT00195429 | Wyeth is now a wholly owned subsidiary of Pfizer |
Kidney Failure|Graft vs Host Disease
|
August 2005 | Phase 4 |
| NCT00388635 | PETHEMA Foundation|Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Multiple Myeloma
|
April 2004 | Phase 1|Phase 2 |
| NCT01760226 | Baylor College of Medicine|National Cancer Institute (NCI) |
Diffuse Large B Cell Lymphoma|Post Transplant Lymphoproliferative Disorder|Primary Mediastinal (Thymic) Large B-cell Lymphoma
|
January 2013 | Early Phase 1 |
| NCT02359162 | Sun Yat-sen University |
Lymphoma, Extranodal NK-T-Cell
|
May 2015 | Phase 3 |
| NCT04451174 | University of Chile |
COVID-19
|
June 23, 2020 | Phase 3 |
| NCT00135967 | Radboud University Medical Center|Hoffmann-La Roche |
Glomerulonephritis, Membranous
|
May 2002 | Phase 2|Phase 3 |
| NCT04339062 | Dana-Farber Cancer Institute|Regeneron Pharmaceuticals |
Cutaneous Squamous Cell Carcinoma|Advanced Cancer
|
July 15, 2020 | Phase 1 |
| NCT02481310 | Northwestern University|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc. |
Adult Burkitt Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|MYC Gene Mutation|Plasmablastic Lymphoma
|
October 28, 2015 | Phase 1|Phase 2 |
| NCT02849990 | University of Washington|Janssen Scientific Affairs, LLC|National Cancer Institute (NCI) |
Stage III Prostate Adenocarcinoma AJCC v7|Stage III Prostate Cancer AJCC v7|Stage IV Prostate Adenocarcinoma AJCC v7|Stage IV Prostate Cancer AJCC v7
|
March 9, 2017 | Phase 2 |
| NCT03153527 | University Hospital, Basel, Switzerland|Kantonsspital Baselland Bruderholz|Swiss National Science Foundation|HEMMI Stiftung Switzerland |
Inflammatory Disorder|Autoimmune
|
May 31, 2017 | Phase 4 |
| NCT02449265 | Wuhan University |
Diffuse Large B-cell Lymphoma
|
October 2015 | Phase 3 |
| NCT03439670 | ReveraGen BioPharma, Inc.|European Union|Cooperative International Neuromuscular Research Group|Newcastle University|University of Pittsburgh |
Duchenne Muscular Dystrophy
|
June 19, 2018 | Phase 2 |
| NCT02298335 | Nanjing University School of Medicine |
Nephrotic Syndrome?Idiopathic
|
May 13, 2014 | Not Applicable |
| NCT01411514 | Claudio Gobbi|Ente Ospedaliero Cantonale, Ticino, Switzerland|Ospedale Civico, Lugano |
Multiple Sclerosis
|
August 2011 | Phase 4 |
| NCT00873093 | National Cancer Institute (NCI) |
B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia
|
March 2009 | Phase 2 |
| NCT00452387 | Accelerated Community Oncology Research Network|Bayer |
Metastatic Prostate Cancer
|
May 2007 | Phase 2 |
| NCT00580229 | University of South Florida |
Rheumatoid Arthritis
|
December 2007 | Phase 2|Phase 3 |
| NCT00014339 | Medsearch|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
March 2000 | Phase 3 |
| NCT01193049 | Merck Sharp & Dohme LLC |
Asthma
|
August 2010 | Phase 1 |
| NCT05167175 | Hongqian Guo|AstraZeneca|Nanjing Chia-tai Tianqing Pharmaceutical|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Prostate Cancer|Prostate Carcinoma|Metastatic Prostate Cancer
|
March 1, 2022 | Phase 2 |
| NCT05039619 | Hoffmann-La Roche|Genentech, Inc. |
Lupus Nephritis
|
May 12, 2022 | Phase 2 |
| NCT05466175 | Chen Suning|The First Affiliated Hospital of Soochow University |
Philadelphia-Positive ALL
|
October 1, 2022 | Phase 2 |
| NCT00357084 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Cancer
|
May 2006 | Phase 2 |
| NCT02541565 | University of Washington|National Cancer Institute (NCI) |
Composite Lymphoma|Grade 3b Follicular Lymphoma|Stage I Diffuse Large B-Cell Lymphoma|Stage I Follicular Lymphoma|Stage II Diffuse Large B-Cell Lymphoma|Stage II Follicular Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage III Follicular Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma|Stage IV Follicular Lymphoma
|
November 24, 2015 | Phase 1 |
| NCT03584516 | Incyte Corporation |
Chronic Graft-versus-host Disease
|
January 17, 2019 | Phase 2|Phase 3 |
| NCT01920932 | St. Jude Children´s Research Hospital|Seagen Inc. |
Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma
|
August 12, 2013 | Phase 2 |
| NCT05003713 | Corcept Therapeutics |
Healthy
|
August 3, 2021 | Phase 1 |
| NCT04988256 | University of Southern California |
DRESS Syndrome|Drug-Induced Hypersensitivity Syndrome
|
September 27, 2021 | Early Phase 1 |
| NCT04790903 | Hoffmann-La Roche |
Lymphoma, Large B-Cell, Diffuse
|
July 2, 2021 | Phase 1 |
| NCT01485861 | Genentech, Inc. |
Prostate Cancer
|
January 11, 2012 | Phase 1|Phase 2 |
| NCT02534402 | University of British Columbia |
Chronic Obstructive Pulmonary Disease
|
August 2015 | Phase 4 |
| NCT04739813 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma|Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Burkitt Lymphoma
|
July 9, 2021 | Phase 1 |
| NCT02784210 | National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) |
Multiple Sclerosis
|
October 5, 2016 | Phase 2 |
| NCT00070083 | British Columbia Cancer Agency|National Cancer Institute (NCI) |
Lymphoma
|
July 2003 | Phase 1 |
| NCT04882683 | Shandong Qilu Stem Cells Engineering Co., Ltd. |
Ulcerative Colitis
|
June 1, 2021 | Not Applicable |
| NCT04788823 | Charitable Union for the Research and Education of Peyronie´s Disease |
Vasectomy Reversal
|
February 24, 2021 | Phase 4 |
| NCT00169156 | Lymphoma Study Association|Hoffmann-La Roche |
Untreated T-cell Angioimmunoblastic Lymphoma
|
December 2005 | Phase 2 |
| NCT01390584 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lymphoma
|
April 2, 2012 | Phase 2 |
| NCT02918747 | Hunan Cancer Hospital |
Lymphoma
|
September 2016 | Phase 2 |
| NCT03133897 | Children´s Hospital of Eastern Ontario |
Asthma
|
March 5, 2018 | Phase 3 |
| NCT02844582 | University of California, Davis|Sanofi |
Hormone-Resistant Prostate Cancer|Stage IV Prostate Adenocarcinoma
|
December 20, 2017 | Phase 2 |
| NCT01714817 | Bristol-Myers Squibb |
Lupus Nephritis
|
January 22, 2013 | Phase 3 |
| NCT04887506 | Tavanta Therapeutics |
Metastatic Castration-resistant Prostate Cancer|Metastatic Castration-sensitive Prostate Cancer|Metastatic Prostate Cancer
|
April 14, 2021 | Phase 3 |
| NCT01741753 | Dana-Farber Cancer Institute |
Prostate Cancer
|
November 2012 | Phase 1 |
| NCT01946880 | National Institute of Allergy and Infectious Diseases (NIAID)|Autoimmunity Centers of Excellence|Rho Federal Systems Division, Inc. |
Systemic Lupus Erythematosus|SLE
|
November 20, 2013 | Phase 2 |
| NCT00004448 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Southwest Pediatric Nephrology Study Group|Office of Rare Diseases (ORD) |
IGA Glomerulonephritis
|
November 1997 | Phase 2 |
| NCT05188911 | Fudan University |
Prostate Cancer|Castration-resistant Prostate Cancer|Metastatic Disease
|
July 15, 2020 | |
| NCT02529852 | M.D. Anderson Cancer Center|Celgene|Genentech, Inc. |
Lymphoma
|
November 4, 2015 | Phase 1|Phase 2 |
| NCT00551291 | Hoffmann-La Roche |
Myelodysplastic Syndromes
|
August 2007 | Phase 2 |
| NCT00003633 | Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) |
Prostate Cancer
|
August 1998 | Phase 1 |
| NCT03617432 | Peking University|Peking University International Hospital|Shandong Tumor Hospital|Jiangxi Provincial Cancer Hospital |
Experimental Tumor
|
August 28, 2018 | Phase 2 |
| NCT02776436 | Leiden University Medical Center |
Breast Cancer|Prostate Cancer
|
January 2016 | Phase 1 |
| NCT02200146 | University of Milano Bicocca|Agenzia Italiana del Farmaco |
Pulmonary Sarcoidosis
|
March 2009 | Phase 3 |
| NCT01848132 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Janssen-Cilag, S.A. |
Diffuse, Large B-Cell, Lymphoma
|
October 3, 2013 | Phase 2 |
| NCT01992653 | Genentech, Inc. |
Lymphoma, Non Hodgkin
|
November 29, 2013 | Phase 1|Phase 2 |
| NCT03706365 | Eli Lilly and Company |
Prostate Cancer
|
November 26, 2018 | Phase 2|Phase 3 |
| NCT02334813 | University Hospital, Essen |
Purpura, Thrombocytopenic, Idiopathic
|
July 2002 | Phase 3 |
| NCT02871869 | Xinjiang Medical University |
Diffuse, Large B-Cell, Lymphoma
|
September 2016 | Phase 2|Phase 3 |
| NCT01188187 | Achieve Life Sciences|Teva Branded Pharmaceutical Products R&D, Inc. |
Prostate Cancer
|
November 2010 | Phase 3 |
| NCT00972660 | Guangdong Provincial People´s Hospital|Sun Yat-sen University |
Graft Versus Host Disease
|
September 2009 | Phase 2 |
| NCT04043494 | University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany) |
Lymphoblastic Lymphoma, Childhood
|
August 23, 2019 | Phase 3 |
| NCT04668365 | Henan Cancer Hospital |
Diffuse Large B Cell Lymphoma|CD79A Gene Mutation|CD79B Gene Mutation
|
December 25, 2020 | Phase 2 |
| NCT05283720 | AbbVie|Genmab |
Non-Hodgkin Lymphoma
|
June 14, 2022 | Phase 2 |
| NCT02767674 | The First Affiliated Hospital with Nanjing Medical University |
Diffuse Large B Cell Lymphoma
|
May 2016 | Phase 3 |
| NCT03269747 | University Hospital, Basel, Switzerland |
Brown Adipose Tissue
|
December 6, 2017 | Phase 4 |
| NCT00104299 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Genentech, Inc. |
Vasculitis|Wegener´s Granulomatosis|Microscopic Polyangiitis
|
January 2005 | Phase 2|Phase 3 |
| NCT00774852 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Lupus Nephritis|Lupus Erythematosus, Systemic
|
November 2008 | Phase 2 |
| NCT02116556 | Hospital Universitari Vall d´Hebron Research Institute|Germans Trias i Pujol Hospital|Hospital del Mar|Hospital de Sant Pau |
Alcoholic Hepatitis
|
April 2013 | Phase 2 |
| NCT02773550 | Basque Health Service |
Multiple Myeloma
|
January 2014 | Phase 4 |
| NCT05371093 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory Follicular Lymphoma
|
September 12, 2022 | Phase 3 |
| NCT02206425 | Oncotherapeutics|Takeda |
Multiple Myeloma
|
September 2014 | Phase 1|Phase 2 |
| NCT03467373 | Hoffmann-La Roche |
B-Cell Lymphoma|Non-Hodgkin Lymphoma
|
March 13, 2018 | Phase 1 |
| NCT04992026 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The Affiliated Hospital of Xuzhou Medical University|The First People´s Hospital of Changzhou|The First Affiliated Hospital of Soochow University|Wuxi People´s Hospital|The Affiliated Hospital of Nantong University|The Affiliated Hospital of Yangzhou University |
Prostatectomy|Oligometastatic Prostate Cancer|Abiraterone
|
January 1, 2021 | Phase 2 |
| NCT01920737 | Memorial Sloan Kettering Cancer Center|Shire|Duke University|Weill Medical College of Cornell University|Lehigh Valley Health Network |
Leukemia
|
August 2013 | Phase 2 |
| NCT02237820 | Rabin Medical Center |
Heart Failure|Chronic Obstructive Pulmonary Disease
|
November 2014 | Phase 4 |
| NCT00544440 | Janssen Research & Development, LLC |
Prostate Neoplasms
|
October 2007 | Phase 2 |
| NCT04795583 | University of Alberta |
Covid19
|
August 1, 2021 | Phase 3 |
| NCT04433156 | Henan Cancer Hospital |
Marginal Zone Lymphoma
|
April 22, 2020 | Phase 2 |
| NCT01605227 | Exelixis |
Prostate Cancer|Castration Resistant Prostate Cancer|Pain|Prostatic Neoplasms
|
July 2012 | Phase 3 |
| NCT01786265 | M.D. Anderson Cancer Center |
Prostate Adenocarcinoma|Recurrent Prostate Carcinoma
|
February 5, 2013 | Phase 2 |
| NCT02921555 | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa |
Ulcerative Colitis
|
October 11, 2018 | Phase 4 |
| NCT01452100 | University Hospital, Toulouse|Ministry of Health, France |
Cholesterol Embolism Systemic
|
June 2011 | Phase 2 |
| NCT03750383 | Enanta Pharmaceuticals, Inc|Pharmaceutical Research Associates |
RSV Infection
|
November 2, 2018 | Phase 1 |
| NCT04759586 | National Cancer Institute (NCI) |
Primary Mediastinal (Thymic) Large B-Cell Lymphoma
|
June 7, 2021 | Phase 3 |
| NCT01287741 | Hoffmann-La Roche|Fondazione Italiana Linfomi ONLUS |
Diffuse Large B-Cell Lymphoma
|
July 26, 2011 | Phase 3 |
| NCT01424982 | M.D. Anderson Cancer Center |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Untreated Adult Acute Lymphoblastic Leukemia
|
October 5, 2011 | Phase 2 |
| NCT02908698 | McMaster University |
Atopic Dermatitis
|
January 24, 2017 | Not Applicable |
| NCT00789997 | Ottawa Hospital Research Institute |
COPD Exacerbation
|
November 2008 | Phase 2|Phase 3 |
| NCT03589326 | Takeda |
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph&addition;ALL)
|
August 10, 2018 | Phase 3 |
| NCT04453345 | Institute of Hematology & Blood Diseases Hospital|The First Affiliated Hospital of Nanchang University|First Affiliated Hospital of Guangxi Medical University|Henan Cancer Hospital|The First Hospital of Jilin University|Central South University|Tianjin First Central Hospital |
T-LGL Leukemia|Clpd-Nk
|
May 20, 2013 | Phase 2|Phase 3 |
| NCT04660565 | Peking Union Medical College Hospital |
IgG4-related Disease
|
January 2021 | Phase 4 |
| NCT02043587 | University of California, San Diego|Leadiant Biosciences, Inc. |
Acute Lymphocytic Leukemia|Adult Lymphoblastic Lymphoma
|
January 2014 | Phase 2 |
| NCT00004001 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|North Central Cancer Treatment Group |
Prostate Cancer
|
October 1999 | Phase 3 |
| NCT00983944 | Ohio State University Comprehensive Cancer Center |
Lymphoma
|
September 2009 | Phase 2 |
| NCT01004991 | Weill Medical College of Cornell University|Celgene |
Diffuse Large B Cell Lymphoma
|
January 2010 | Phase 1|Phase 2 |
| NCT03217812 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 23, 2017 | Phase 3 |
| NCT03962465 | University of Virginia|Pfizer|Vanderbilt University|University of Wisconsin, Madison|Virginia Commonwealth University |
B-cell Acute Lymphoblastic Leukemia
|
July 22, 2022 | Phase 1 |
| NCT03360721 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Castration-Resistant Prostate Carcinoma|Prostate Adenocarcinoma Without Neuroendocrine Differentiation|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8
|
March 6, 2018 | Phase 2 |
| NCT01234025 | Ionis Pharmaceuticals, Inc. |
Castrate-Resistant Prostate Cancer
|
November 2010 | Phase 1|Phase 2 |
| NCT00000524 | University of Utah|National Heart, Lung, and Blood Institute (NHLBI) |
Cardiovascular Diseases|Heart Diseases|Myocarditis
|
July 1986 | Phase 2 |
| NCT04536662 | Shanghai Jiao Tong University School of Medicine |
Congenital Adrenal Hyperplasia
|
October 1, 2020 | Phase 4 |
| NCT03934840 | Masonic Cancer Center, University of Minnesota |
Prostate Cancer
|
October 10, 2019 | Phase 2 |
| NCT00389818 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC |
Lymphoma
|
January 2007 | Phase 2 |
| NCT03761225 | AB Science |
Metastatic Castrate Resistant Prostate Cancer
|
September 2014 | Phase 3 |
| NCT00098839 | Children´s Oncology Group|National Cancer Institute (NCI) |
Recurrent Childhood Acute Lymphoblastic Leukemia
|
February 2005 | Phase 1|Phase 2 |
| NCT03012321 | Northwestern University|AstraZeneca|National Cancer Institute (NCI) |
Prostate Cancer Metastatic Castration-Resistant|Abnormal DNA Repair|Metastatic Prostate Carcinoma|Stage IV Prostate Cancer
|
January 2017 | Phase 2 |
| NCT00526305 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
January 2000 | Phase 4 |
| NCT00642018 | Eli Lilly and Company |
Prostate Cancer
|
March 2008 | Phase 2 |
| NCT01063179 | Fondazione EMN Italy Onlus |
Multiple Myeloma
|
May 2006 | Phase 3 |
| NCT00003262 | Centro di Riferimento Oncologico - Aviano|National Cancer Institute (NCI) |
Lymphoma
|
May 1997 | Phase 2 |
| NCT04231877 | University of Washington|Genentech, Inc. |
Aggressive Non-Hodgkin Lymphoma|ALK-Positive Large B-Cell Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma
|
October 27, 2020 | Phase 1 |
| NCT00376961 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
August 2006 | Phase 2 |
| NCT00919243 | Hebei Medical University |
Heart Failure|Hyperuricemia
|
February 2009 | Phase 4 |
| NCT00623766 | Bristol-Myers Squibb|Medarex |
Melanoma
|
July 2008 | Phase 2 |
| NCT00002548 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group |
Multiple Myeloma
|
January 1994 | Phase 3 |
| NCT02036463 | Ann & Robert H Lurie Children´s Hospital of Chicago|Children´s National Research Institute |
Duchenne Muscular Dystrophy (DMD)
|
November 2014 | Phase 2 |
| NCT00227591 | National Cancer Institute (NCI) |
Essential Thrombocythemia|Polycythemia Vera|Primary Myelofibrosis
|
December 2005 | Phase 2 |
| NCT00562159 | ALK-Abelló A+S |
Rhinoconjunctivitis|Rhinitis|Conjunctivitis|Allergy
|
November 2007 | Phase 3 |
| NCT02218606 | Memorial Sloan Kettering Cancer Center|Sanofi|Thomas Jefferson University|Weill Medical College of Cornell University |
Prostate Cancer
|
August 2014 | Phase 2 |
| NCT03255473 | University of Colorado, Denver |
Sudden Sensorineural Hearing Loss (SSNHL)
|
August 30, 2017 | Phase 2 |
| NCT01378091 | Columbia University|Celgene Corporation |
Prostate Cancer
|
August 2005 | Phase 1 |
| NCT01972217 | AstraZeneca|Merck Sharp & Dohme LLC |
Metastatic Castration-resistant Prostate Cancer
|
April 1, 2014 | Phase 2 |
| NCT03828682 | Simon Tremblay, PharmD, PhD|Veloxis Pharmaceuticals|University of Cincinnati |
Kidney Transplantation|Immunosuppression
|
June 21, 2019 | Phase 4 |
| NCT01385228 | Daniel George, MD|GlaxoSmithKline|Duke University |
Prostate Cancer
|
June 2011 | Phase 1 |
| NCT03847649 | Canadian Cancer Trials Group|AstraZeneca |
Cancer
|
June 7, 2019 | Phase 2 |
| NCT02474563 | Janssen Korea, Ltd., Korea |
Multiple Myeloma
|
May 2011 | |
| NCT00369356 | Universita di Verona|Regione Piemonte |
Coronary Artery Disease|Ischemic Heart Disease|Atherosclerosis
|
October 2006 | Phase 2|Phase 3 |
| NCT01309789 | Seagen Inc.|Millennium Pharmaceuticals, Inc. |
Lymphoma, Large-Cell, Anaplastic|Lymphoma, NK-cell|Lymphoma, T-cell
|
February 2011 | Phase 1 |
| NCT05156450 | West China Hospital |
Prostatic Neoplasms, Castration-Resistant|Drug Therapy, Combination
|
January 1, 2022 | Phase 2 |
| NCT00520468 | M.D. Anderson Cancer Center |
Myelodysplastic Syndrome
|
June 2004 | Phase 2 |
| NCT04660799 | Hoffmann-La Roche |
Lymphoma, Large B-Cell, Diffuse
|
February 24, 2021 | Phase 2 |
| NCT01818752 | Amgen |
Multiple Myeloma
|
July 8, 2013 | Phase 3 |
| NCT02213913 | University of Chicago|National Cancer Institute (NCI) |
Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia
|
July 29, 2014 | Phase 1|Phase 2 |
| NCT04974996 | ADC Therapeutics S.A. |
Diffuse Large B-Cell Lymphoma
|
February 1, 2022 | Phase 1 |
| NCT03121690 | Assiut University |
Pneumonia Hospital Acquired
|
December 1, 2017 | Phase 4 |
| NCT02097303 | Carolina Research Professionals, LLC|Bayer |
Prostate Cancer
|
March 2014 | Phase 2 |
| NCT03943901 | University of Wisconsin, Madison|Medical College of Wisconsin |
Diffuse Large B Cell Lymphoma|DLBCL|Cancer
|
February 16, 2021 | Phase 2 |
| NCT00273559 | Florida Hospital Transplant Center|Genzyme, a Sanofi Company|Novartis |
Kidney Diseases
|
January 2006 | |
| NCT01017939 | Janssen Research & Development, LLC |
Prostate Neoplasms
|
January 2010 | Phase 1 |
| NCT04691804 | Jiangsu HengRui Medicine Co., Ltd. |
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
March 18, 2021 | Phase 3 |
| NCT02990403 | Shanghai First Maternity and Infant Hospital |
Recurrent Pregnancy Loss
|
October 2014 | Phase 4 |
| NCT00003784 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
May 1999 | Phase 2 |
| NCT04249323 | Corcept Therapeutics |
Healthy Adults
|
January 27, 2020 | Phase 1 |
| NCT01579110 | Institute of Hematology & Blood Diseases Hospital |
Anemia|Anemia, Hemolytic|Anemia, Hemolytic, Autoimmune|Hemolysis|Hematologic Diseases|Autoimmune Diseases|Immune System Diseases|Pathologic Processes
|
April 2012 | Phase 2 |
| NCT05405439 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Metastatic Castration-resistant Prostate Cancer
|
June 2022 | Phase 1|Phase 2 |
| NCT00385827 | Centocor, Inc. |
Cancer, Prostate
|
November 2006 | Phase 2 |
| NCT03536039 | Andres J. M. Ferreri|AGC Biologics S.p.A.|IRCCS San Raffaele |
Lymphoma, Large B-Cell, Diffuse
|
January 27, 2016 | Phase 2 |
| NCT01133626 | Teva Branded Pharmaceutical Products R&D, Inc. |
Perennial Allergic Rhinitis
|
June 2010 | Phase 3 |
| NCT01659099 | The Lymphoma Academic Research Organisation|Hoffmann-La Roche |
Diffuse Large B Cell Lymphoma CD20 Positive
|
September 2012 | Phase 3 |
| NCT01308580 | Sanofi |
Prostate Cancer
|
April 2011 | Phase 3 |
| NCT02758132 | University of Hawaii |
Prostate Cancer
|
March 1, 2016 | Phase 2 |
| NCT02036489 | PETHEMA Foundation |
Acute Lymphobkastic Leukemia
|
January 2008 | Phase 4 |
| NCT00274924 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 2006 | Phase 2 |
| NCT00209222 | European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association |
Lymphoma, Mantle-Cell
|
July 2004 | Phase 3 |
| NCT03833596 | McMaster University|Nestlé |
Crohn´s Disease
|
October 25, 2018 | Phase 4 |
| NCT01451515 | St. Jude Children´s Research Hospital|National University, Singapore |
Lymphoblastic Lymphoma
|
May 25, 2012 | Phase 2 |
| NCT00004482 | Mayo Clinic |
Myocarditis|Giant Cell Myocarditis
|
December 1999 | Phase 2 |
| NCT00002653 | Medical Research Council|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
September 1993 | Phase 3 |
| NCT00002618 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
December 1994 | Phase 3 |
| NCT01117441 | University Hospital Schleswig-Holstein|Deutsche Krebshilfe e.V., Bonn (Germany) |
Leukemia
|
June 2010 | Phase 3 |
| NCT00110669 | Cooperative International Neuromuscular Research Group |
Duchenne Muscular Dystrophy
|
January 2004 | Phase 3 |
| NCT00002714 | Stanford University|National Cancer Institute (NCI) |
Lymphoma
|
April 1995 | Phase 2 |
| NCT00003554 | The Cleveland Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
November 1998 | Phase 2 |
| NCT03504241 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|PPD|Rho Federal Systems Division, Inc. |
Kidney Transplantation|Renal Transplantation|Renal Transplant Recipient
|
July 30, 2018 | Phase 1 |
| NCT03687515 | Beijing Tongren Hospital |
Chronic Rhinosinusitis With Polyposis
|
January 1, 2015 | Phase 3 |
| NCT00459186 | Dana-Farber Cancer Institute|Novartis|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Oregon Health and Science University |
Metastatic, Androgen Independent Prostate Cancer|Prostate Cancer
|
November 2005 | Phase 1|Phase 2 |
| NCT02953873 | Medical University of South Carolina|Astellas Pharma Inc |
Immunosuppression
|
May 5, 2017 | Phase 4 |
| NCT03816332 | National Cancer Institute (NCI) |
Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage III Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Clinical Stage IV Merkel Cell Carcinoma AJCC v8|Metastatic Basal Cell Carcinoma|Metastatic Melanoma|Metastatic Merkel Cell Carcinoma|Metastatic Skin Squamous Cell Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage III Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Pathologic Stage IV Merkel Cell Carcinoma AJCC v8|Unresectable Basal Cell Carcinoma|Unresectable Melanoma|Unresectable Merkel Cell Carcinoma
|
February 1, 2019 | Phase 1 |
| NCT00002756 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
June 1996 | Phase 2 |
| NCT01603407 | University of Rochester|Newcastle University|University Medical Center Freiburg|National Institute of Neurological Disorders and Stroke (NINDS) |
Duchenne Muscular Dystrophy
|
January 2013 | Phase 3 |
| NCT00690560 | Centre Antoine Lacassagne |
Lymphoma
|
May 2007 | Phase 2 |
| NCT02561273 | University of Nebraska|National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Hepatosplenic T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Stage II Angioimmunoblastic T-cell Lymphoma|Stage II Enteropathy-Associated T-Cell Lymphoma|Stage III Angioimmunoblastic T-cell Lymphoma|Stage III Enteropathy-Associated T-Cell Lymphoma|Stage IV Angioimmunoblastic T-cell Lymphoma|Stage IV Enteropathy-Associated T-Cell Lymphoma
|
October 2015 | Phase 1|Phase 2 |
| NCT00288080 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Prostate Cancer
|
December 2005 | Phase 3 |
| NCT03315338 | Corcept Therapeutics |
Healthy
|
September 15, 2017 | Phase 1 |
| NCT00002715 | Stanford University|National Cancer Institute (NCI) |
Lymphoma
|
April 1989 | Phase 2 |
| NCT04980222 | Hoffmann-La Roche |
Lymphoma
|
March 22, 2022 | Phase 2 |
| NCT03981081 | Hôpital Universitaire Fattouma Bourguiba |
Copd Exacerbation Acute|Mechanical Ventilation
|
April 2, 2019 | Phase 4 |
| NCT00028717 | Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI) |
Lymphoma
|
February 2001 | Phase 3 |
| NCT03113500 | City of Hope Medical Center|National Cancer Institute (NCI) |
Adult T-Cell Leukemia+Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Angioimmunoblastic T-Cell Lymphoma|Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified
|
May 25, 2017 | Phase 2 |
| NCT04773392 | University of Southern California|Veloxis Pharmaceuticals |
Kidney Transplantation|Kidney Transplant Rejection
|
November 23, 2021 | Phase 4 |
| NCT00627354 | Groupe D´Etude des Tumeurs Uro-Genitales|National Cancer Institute (NCI) |
Prostate Cancer
|
September 2006 | Phase 2 |
| NCT01369745 | Zalicus |
Rheumatoid Arthritis
|
June 2011 | Phase 2 |
| NCT01336933 | University of Nebraska|National Cancer Institute (NCI)|Spectrum Pharmaceuticals, Inc |
Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma
|
July 2011 | Phase 2 |
| NCT00488605 | University of New Mexico |
Leukemia
|
February 2004 | Phase 3 |
| NCT04542824 | Genmab|AbbVie |
Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma
|
August 20, 2020 | Phase 1|Phase 2 |
| NCT00555464 | Medical College of Wisconsin|FDA Office of Orphan Products Development |
Hemangioma
|
November 2007 | Phase 2 |
| NCT00002494 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
May 1992 | Phase 2 |
| NCT00602641 | National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
February 29, 2008 | Phase 3 |
| NCT00882206 | Masonic Cancer Center, University of Minnesota |
Leukemia|Lymphoma
|
April 2009 | Phase 2 |
| NCT03671174 | RenJi Hospital|The First Affiliated Hospital of Anhui Medical University|China-Japan Union Hospital, Jilin University|Wuxi No. 2 People´s Hospital|The First Affiliated Hospital with Nanjing Medical University|Xiangya Hospital of Central South University |
Undifferentiated Connective Tissue Disease|Recurrent Pregnancy Loss
|
August 2, 2019 | Not Applicable |
| NCT00539838 | Genentech, Inc.|Roche Pharma AG |
Systemic Lupus Erythematosus
|
December 19, 2007 | Phase 3 |
| NCT00026208 | Stanford University |
Lymphoma, Hodgkin Disease|Lymphoma|Hodgkin Disease|Lymphoma: Hodgkin
|
June 2001 | Phase 2 |
| NCT03804723 | University of Pisa |
Systemic Lupus Erythematosus|Glucocorticoids|Therapy Withdrawal
|
June 2019 | Not Applicable |
| NCT00133991 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
July 2005 | Phase 2 |
| NCT00713193 | Ohio State University|Food and Drug Administration (FDA) |
Thrombotic Thrombocytopenic Purpura
|
November 2007 | Phase 3 |
| NCT04654988 | Medical University of Warsaw |
Myocarditis|Heart Failure|Endomyocardial Biopsy|Cardiomyopathies, Secondary|Immunosuppression
|
May 1, 2022 | Phase 4 |
| NCT03649841 | University of Washington|National Cancer Institute (NCI) |
Castration-Sensitive Prostate Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Prostate Carcinoma|Prostate Adenocarcinoma|Prostate Small Cell Neuroendocrine Carcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8
|
June 29, 2020 | Phase 2 |
| NCT01260623 | Lawson Health Research Institute |
Asthma Exacerbation
|
September 9, 2009 | |
| NCT03821792 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Prostate Carcinoma|Prostate Adenocarcinoma|Prostate Carcinoma Metastatic in the Bone|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8
|
July 22, 2019 | Phase 2 |
| NCT04234360 | University Hospital, Montpellier |
COPD Exacerbation
|
October 12, 2021 | Phase 3 |
| NCT00039195 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb|Genentech, Inc. |
Lymphoma
|
November 2006 | Phase 2 |
| NCT01681433 | Costantine Albany|Hoosier Cancer Research Network|Achieve Life Sciences |
Prostate Cancer|Metastatic Castrate-Resistant Prostate Cancer|PSA
|
December 2012 | Phase 2 |
| NCT02981979 | Jiang lindi|Shanghai Zhongshan Hospital |
Takayasu Arteritis
|
December 2016 | Not Applicable |
| NCT02161653 | Hospital General de Mexico |
Severe Alcoholic Hepatitis
|
April 2010 | Phase 4 |
| NCT02753764 | National Jewish Health |
Corticosteroid Resistant (CR) Asthmatics
|
January 2017 | Phase 2 |
| NCT04787744 | VA Office of Research and Development |
Prostate Cancer|Oligometastasis|Oligorecurrence|Recurrent Prostate Cancer|Metastatic Prostate Cancer
|
July 1, 2021 | Phase 2|Phase 3 |
| NCT01072045 | University of Sao Paulo|University of Sao Paulo General Hospital |
Hemangioma
|
January 2010 | Phase 2 |
| NCT01879514 | Shanghai University of Traditional Chinese Medicine|Shanghai 6th People´s Hospital|RenJi Hospital |
IgA Nephropathy
|
January 2010 | Not Applicable |
| NCT00751205 | Bayer |
Prostate Cancer|Ovarian Cancer
|
August 2008 | Phase 2 |
| NCT04812366 | University of British Columbia|Janssen Inc.|University Health Network, Toronto |
Prostate Cancer
|
September 21, 2021 | Phase 2 |
| NCT04548700 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Treatment-naïve|Peripheral T Cell Lymphoma
|
December 24, 2020 | Phase 1 |
| NCT01553188 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic
|
February 8, 2012 | Phase 2 |
| NCT02903368 | Dana-Farber Cancer Institute|Janssen Scientific Affairs, LLC |
Prostate Cancer
|
October 19, 2016 | Phase 2 |
| NCT02562924 | University of Vermont Medical Center |
Chronic Sinusitis|Nasal Polyposis
|
November 2015 | Not Applicable |
| NCT05389423 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Diffuse Large Cell Lymphoma|Non-Hodgkin Lymphoma|Burkitt Lymphoma|Plasmablastic Lymphoma|B-Cell Neoplasm
|
November 28, 2022 | Phase 1 |
| NCT00097448 | Massachusetts Eye and Ear Infirmary|National Institute on Deafness and Other Communication Disorders (NIDCD) |
Sudden Deafness
|
December 2004 | Phase 3 |
| NCT01005758 | Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
January 2009 | Phase 2 |
| NCT00124566 | Eisai Inc. |
Prostate Cancer
|
June 2004 | Phase 2 |
| NCT02166463 | National Cancer Institute (NCI) |
Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma
|
March 16, 2015 | Phase 3 |
| NCT05035862 | Emory University|The Marcus Foundation|Ossium Health, Inc. |
Asthma
|
March 16, 2022 | Phase 1 |
| NCT01254513 | UNICANCER |
Prostate Cancer
|
December 9, 2010 | Phase 2 |
| NCT02690922 | Tongji Hospital |
ph&addition; Acute Lymphoblastic Leukemia
|
March 2016 | Phase 4 |
| NCT00361621 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Millennium Pharmaceuticals, Inc. |
Non-Hodgkin´s Lymphoma
|
July 2006 | Phase 2 |
| NCT05578976 | AbbVie|Genmab |
Diffuse Large B-Cell Lymphoma
|
February 5, 2023 | Phase 3 |
| NCT02809573 | Chipscreen Biosciences, Ltd. |
Peripheral T-cell Lymphoma
|
August 11, 2016 | Phase 1 |
| NCT00313482 | Veeda Oncology|Bayer |
Hormone Refractory Prostate Cancer
|
April 2006 | Phase 2 |
| NCT00147875 | University of Cologne|German Hodgkin´s Lymphoma Study Group|Eli Lilly and Company |
Hodgkin´s Disease
|
March 2004 | Phase 1|Phase 2 |
| NCT05422066 | Li Zhiming|Antengene Corporation|Sun Yat-sen University |
DLBCL Germinal Center B-Cell Type
|
July 26, 2022 | Phase 2 |
| NCT02899026 | GlaxoSmithKline |
Polymyalgia Rheumatica
|
March 15, 2018 | Phase 3 |
| NCT02298283 | The Lymphoma Academic Research Organisation |
Hodgkin Lymphoma
|
April 2015 | Phase 2 |
| NCT00815919 | Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc. |
Chronic Graft Versus Host Disease
|
December 2008 | Phase 2 |
| NCT00161239 | University of Medicine and Dentistry of New Jersey|Ortho Biotech, Inc.|Rutgers, The State University of New Jersey |
T-Cell Lymphoma
|
February 2005 | Not Applicable |
| NCT02260934 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Lupus Nephritis
|
July 9, 2015 | Phase 2 |
| NCT01086540 | National Institute of Allergy and Infectious Diseases (NIAID)|Autoimmunity Centers of Excellence|Rho Federal Systems Division, Inc. |
Systemic Sclerosis-Associated PAH
|
June 24, 2011 | Phase 2 |
| NCT03808610 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory T Acute Lymphoblastic Leukemia
|
April 3, 2019 | Phase 1|Phase 2 |
| NCT00512980 | University of Cologne |
Hodgkin Lymphoma
|
August 2008 | Phase 2 |
| NCT01206452 | Dhanunjaya Lakkireddy, MD, FACC|University of Kansas Medical Center |
Atrial Fibrillation
|
September 2010 | Phase 4 |
| NCT03431350 | Janssen Research & Development, LLC |
Prostatic Neoplasms, Castration-Resistant
|
March 2, 2018 | Phase 1|Phase 2 |
| NCT02453009 | Santa Chiara Hospital |
Prostatic Neoplasms
|
October 2014 | Phase 2 |
| NCT04987450 | Medical University of Lodz |
Glomerular Disease
|
October 1, 2018 | |
| NCT00942578 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Prostate Cancer
|
July 16, 2009 | Phase 2 |
| NCT00002499 | Grupo Argentino de Tratamiento de la Leucemia Aguda|National Cancer Institute (NCI) |
Leukemia
|
January 1990 | Phase 2|Phase 3 |
| NCT00003490 | The Cleveland Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
October 1998 | Phase 2 |
| NCT00002766 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
March 1996 | Phase 3 |
| NCT00004686 | The Cleveland Clinic|FDA Office of Orphan Products Development |
Giant Cell Arteritis
|
February 1994 | Phase 2 |
| NCT02479490 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Metastatic Renal Cancer
|
September 22, 2015 | Phase 2 |
| NCT00004112 | University of Nebraska|National Cancer Institute (NCI) |
Lymphoma
|
September 1999 | Phase 3 |
| NCT01683552 | Campus Bio-Medico University |
ITCH
|
September 2010 | Phase 2 |
| NCT01254864 | M.D. Anderson Cancer Center|Bristol-Myers Squibb|Janssen Scientific Affairs, LLC|Pfizer |
Prostate Cancer
|
March 16, 2011 | Phase 2 |
| NCT00596947 | University of Pennsylvania |
Transplants and Implants
|
October 2005 | Phase 4 |
| NCT03864419 | Fred Hutchinson Cancer Center |
Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma
|
October 24, 2019 | Phase 1 |
| NCT02538926 | University of Washington|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia+Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma
|
July 1, 2018 | Phase 2 |
| NCT04551781 | South Valley University |
Covid19
|
April 1, 2020 | Not Applicable |
| NCT00003204 | National Cancer Institute (NCI) |
Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Small Lymphocytic Lymphoma
|
March 1998 | Phase 3 |
| NCT01685125 | University of Southern California|National Cancer Institute (NCI) |
Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer
|
September 2012 | Phase 2 |
| NCT04907227 | Merck Sharp & Dohme LLC |
Prostatic Neoplasms
|
September 23, 2020 | Phase 3 |
| NCT01197040 | Assistance Publique - Hôpitaux de Paris|Novartis |
Nephrotic Syndrome
|
October 2009 | Phase 3 |
| NCT00137436 | Pfizer |
Prostatic Neoplasms
|
October 2005 | Phase 1|Phase 2 |
| NCT01686464 | Wenzhou Medical University |
Bell´s Palsy
|
June 1998 | Not Applicable |
| NCT02987244 | Peking Union Medical College Hospital|Chinese PLA General Hospital|Peking University First Hospital|Peking University Third Hospital|Peking University Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital |
T Cell Non-Hodgkin´s Lymphoma
|
March 2016 | Phase 1|Phase 2 |
| NCT04752163 | M.D. Anderson Cancer Center |
Hematopoietic and Lymphoid Cell Neoplasm|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Myelodysplastic Syndrome
|
March 25, 2021 | Phase 1|Phase 2 |
| NCT00650078 | Horizon Pharma Ireland, Ltd., Dublin Ireland |
Rheumatoid Arthritis
|
March 2008 | Phase 3 |
| NCT00002744 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
May 1996 | Phase 3 |
| NCT01054313 | M.D. Anderson Cancer Center |
Advanced Cancer
|
January 2010 | Phase 1 |
| NCT04677855 | Pellficure Pharmaceuticals, Inc |
Prostate Cancer
|
March 30, 2021 | Phase 1 |
| NCT05333744 | Peking University People´s Hospital |
Immune Thrombocytopenia
|
June 1, 2021 | Phase 2 |
| NCT02039115 | AdventHealth |
Esophageal Stenosis
|
March 2014 | Phase 4 |
| NCT03274492 | Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma
|
November 16, 2017 | Phase 3 |
| NCT00499018 | Fondazione Italiana Linfomi ONLUS|Centro di Riferimento per l´Epidemiologia e la Prev. Oncologica Piemonte |
Diffuse Large B-Cell Lymphoma|IPI?2
|
January 2006 | Phase 3 |
| NCT01791153 | Hoffmann-La Roche |
Giant Cell Arteritis
|
July 22, 2013 | Phase 3 |
| NCT04947254 | M.D. Anderson Cancer Center |
Prostate Carcinoma|Stage IIC Prostate Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8
|
August 5, 2021 | Phase 2 |
| NCT00398554 | Christine Mauz-Körholz|Martin-Luther-Universität Halle-Wittenberg |
Lymphoma
|
June 2005 | Phase 2 |
| NCT02285062 | Celgene |
Lymphoma, Large B-Cell, Diffuse
|
January 21, 2015 | Phase 3 |
| NCT04679012 | Weill Medical College of Cornell University|Genentech, Inc. |
Richter Syndrome|Chronic Lymphocytic Leukemia
|
September 24, 2021 | Phase 2 |
| NCT03600818 | Sanofi|Regeneron Pharmaceuticals |
Polymyalgia Rheumatica
|
October 9, 2018 | Phase 3 |
| NCT04633252 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Cancer Of Prostate|Prostate Neoplasms
|
February 23, 2021 | Phase 1|Phase 2 |
| NCT00001212 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) |
Nephrotic Syndrome|Systemic Lupus Erythematosus
|
November 1986 | Phase 2 |
| NCT00676650 | Pfizer |
Prostatic Neoplasms
|
July 2008 | Phase 3 |
| NCT00477750 | Mayo Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
June 2005 | Phase 1|Phase 2 |
| NCT02780479 | University of Florida |
Asthma|Status Asthmaticus|Wheezes
|
March 20, 2017 | Phase 4 |
| NCT03098823 | Ampel BioSolutions, LLC |
Lupus Erythematosus, Systemic|Lupus Erythematosus|Fatigue
|
September 12, 2017 | Phase 4 |
| NCT04542278 | University of Wisconsin, Madison |
Thyroid Diseases
|
November 13, 2020 | Phase 4 |
| NCT02797717 | GALIA AVRAHAMI|University of Giessen|Rabin Medical Center |
Classical Hodgkins Lymphoma in Children and Adolescents.
|
November 2015 | Not Applicable |
| NCT00000146 | National Eye Institute (NEI) |
Multiple Sclerosis|Optic Neuritis
|
July 1988 | Phase 3 |
| NCT00693381 | Astellas Pharma Inc |
Kidney Transplantation
|
February 2003 | Phase 3 |
| NCT05200312 | The First Affiliated Hospital with Nanjing Medical University |
Non Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma
|
February 1, 2022 | Phase 2 |
| NCT01685268 | Astex Pharmaceuticals, Inc. |
Prostate Cancer
|
September 2012 | Phase 1|Phase 2 |
| NCT01946165 | M.D. Anderson Cancer Center|Janssen Services, LLC|Medivation, Inc. |
Prostate Cancer
|
October 31, 2013 | Phase 2 |
| NCT05288166 | Eli Lilly and Company |
Prostatic Neoplasms|Neoplasm Metastasis|Urogenital Neoplasms|Physiological Effects of Drugs|Antineoplastic Agents|Antineoplastic Agents, Hormonal|Androgens|Hormones|Hormones, Hormone Substitutes, and Hormone Antagonists|Abiraterone Acetate|Steroid Synthesis Inhibitors|Cytochrome P-450|Enzyme Inhibitors|Prednisone|Prednisolone|Cyclin-Dependent Kinase 4|Cyclin-Dependent Kinase 6
|
April 14, 2022 | Phase 3 |
| NCT00012207 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
September 2000 | Phase 1 |
| NCT01782859 | Hospital for Special Surgery, New York |
Total Hip Replacement
|
October 2012 | Not Applicable |
| NCT05201248 | AbbVie|Genmab |
B-Cell Non-Hodgkin Lymphoma
|
March 10, 2022 | Phase 1 |
| NCT03263650 | M.D. Anderson Cancer Center|AstraZeneca|Merck Sharp & Dohme LLC |
Prostate Cancer Aggressiveness|Prostate Carcinoma
|
October 3, 2017 | Phase 2 |
| NCT02703194 | Chinese PLA General Hospital |
Immunoglobulin G4 Related Sclerosing Disease
|
March 2016 | Phase 4 |
| NCT00006184 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Multiple Myeloma
|
February 8, 2001 | Phase 2 |
| NCT00268515 | National Heart, Lung, and Blood Institute (NHLBI) |
Lung Diseases
|
April 1998 | Phase 2 |
| NCT01468740 | Harlachinger Krebshilfe e.V.|Deutsche AIDS Gesellschaft e.V. |
HIV-associated Hodgkin Lymphoma
|
March 2004 | Phase 2 |
| NCT01381874 | Janssen Research & Development, LLC |
Metastatic ER&addition; Her2- Breast Cancer|Postmenopausal
|
August 24, 2011 | Phase 2 |
| NCT05376722 | Hongqian Guo|First Affiliated Hospital of Zhejiang University|The First Affiliated Hospital of Soochow University|Nanjing First Hospital, Nanjing Medical University|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Neoadjuvant Therapy
|
February 22, 2022 | Phase 2 |
| NCT00408005 | National Cancer Institute (NCI) |
T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma
|
January 22, 2007 | Phase 3 |
| NCT00333008 | The Alvin and Lois Lapidus Cancer Institute|Ortho Biotech Products, L.P. |
Diffuse Large B Cell Lymphoma|Lymphoma, Non-Hodgkin
|
May 2006 | Phase 2 |
| NCT02883049 | National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|Central Nervous System Leukemia|Ph-Like Acute Lymphoblastic Leukemia|Testicular Leukemia
|
February 27, 2012 | Phase 3 |
| NCT05284942 | Tongji Hospital |
Rosai-Dorfman Disease|Langerhans Cell Histiocytosis
|
October 1, 2011 | Phase 4 |
| NCT02806947 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program |
Acute GVHD
|
October 2016 | Phase 2 |
| NCT00792948 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Adult L1 Acute Lymphoblastic Leukemia|Adult L2 Acute Lymphoblastic Leukemia|Adult T Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia
|
September 1, 2009 | Phase 2 |
| NCT02324699 | Icahn School of Medicine at Mount Sinai|Takeda |
Crohn´s Disease
|
April 2016 | Phase 4 |
| NCT05223582 | Fudan University |
High-risk Prostate Cancer|Neoadjuvant Therapy
|
May 1, 2021 | Phase 2 |
| NCT01051570 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Prostate Cancer
|
February 2010 | Phase 2 |
| NCT05487599 | Prevail Therapeutics|Eli Lilly and Company |
Gaucher Disease
|
August 2022 | Phase 1|Phase 2 |
| NCT03511196 | H. Lee Moffitt Cancer Center and Research Institute |
Prostate Cancer|Stage IV Prostate Cancer|Advanced Prostate Cancer|Adenocarcinoma of the Prostate
|
September 17, 2018 | Early Phase 1 |
| NCT00770848 | Amgen |
Cancer|Castrate-Resistant Prostate Cancer|Mestastatic Prostate Cancer|Prostate Cancer
|
November 2008 | Phase 1|Phase 2 |
| NCT02294357 | Oncotherapeutics|Amgen |
Multiple Myeloma
|
December 2014 | Phase 2 |
| NCT00770224 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 2009 | Phase 2 |
| NCT03304626 | University of Cincinnati|American College of Gastroenterology |
Acute Cellular Graft Rejection|New Onset Diabetes After Transplant
|
June 27, 2017 | Phase 2 |
| NCT02123758 | Aragon Pharmaceuticals, Inc. |
Prostatic Neoplasms|Metastatic Castration-Resistant Prostate Cancer
|
July 9, 2014 | Phase 1 |
| NCT03661684 | John H. Stroger Hospital |
Diabetes|Hyperglycemia Steroid-induced
|
June 3, 2016 | Early Phase 1 |
| NCT00399087 | AEterna Zentaris |
Neoplasms
|
November 2004 | Phase 1 |
| NCT05522465 | Fujian Medical University Union Hospital|The First Affiliated Hospital of Xiamen University|Zhangzhou Affiliated Hospital of Fujian Medical University|Quanzhou First Hospital Affiliated to Fujian Medical University|Nanping First Hospital Affiliated to Fujian Medical University|The Second Hospital of Anhui Medical University|The Affiliated Hospital Of Guizhou Medical University|Longyan City First Hospital|The Affiliated Hospital of Putian University |
Immune Thrombocytopenia|Glucocorticoids|Child, Only
|
September 1, 2022 | Phase 4 |
| NCT00022945 | Corixa Corporation |
Mantle Cell Lymphoma
|
Phase 2 | |
| NCT03508440 | University of Missouri-Columbia |
Bell´s Palsy|Facial Nerve Paresis
|
January 31, 2018 | Phase 2|Phase 3 |
| NCT03505762 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
B-Cell Non-Hodgkin Lymphoma
|
July 19, 2018 | Phase 2 |
| NCT03829371 | University of Turin, Italy |
Multiple Myeloma
|
January 3, 2019 | Phase 4 |
| NCT02184299 | Boehringer Ingelheim |
HIV Infections
|
April 1999 | Phase 4 |
| NCT03749018 | David Bond, MD|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center |
Aggressive Non-Hodgkin Lymphoma|Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Indolent Non-Hodgkin Lymphoma|Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Transformed Non-Hodgkin Lymphoma
|
January 2, 2019 | Phase 2 |
| NCT01886209 | Vertex Pharmaceuticals Incorporated |
Drug Interactions
|
June 2013 | Phase 1 |
| NCT01717898 | Charles Ryan|Novartis Pharmaceuticals|University of California, San Francisco |
Castrate-resistant Prostate Cancer
|
January 31, 2013 | Phase 1|Phase 2 |
| NCT00537381 | Centocor, Inc. |
Prostatic Neoplasms
|
May 2007 | Phase 2 |
| NCT00973154 | University Hospital, Basel, Switzerland|Kantonsspital Aarau|Kantonsspital Liestal |
Community-acquired Pneumonia
|
December 2009 | Phase 3 |
| NCT00896519 | French Innovative Leukemia Organisation|National Cancer Institute (NCI) |
Lymphoma
|
March 2009 | Phase 2 |
| NCT03860987 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Castrate Sensitive Prostate Cancer
|
April 30, 2019 | Phase 2 |
| NCT02208583 | Tianjin Medical University Cancer Institute and Hospital |
Hormone Refractory Prostate Cancer
|
June 2014 | Not Applicable |
| NCT00433459 | Christine Mauz-Körholz|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide|Martin-Luther-Universität Halle-Wittenberg |
Lymphoma
|
January 2007 | Phase 3 |
| NCT00866307 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
February 23, 2009 | Phase 1 |
| NCT00141037 | National Institute of Allergy and Infectious Diseases (NIAID)|Astellas Pharma Inc|Hoffmann-La Roche |
Kidney Diseases|Kidney Transplantation|Kidney Transplant|Renal Transplantation|Renal Transplant
|
March 2004 | Phase 1|Phase 2 |
| NCT02485691 | Sanofi |
Prostate Cancer Metastatic
|
November 9, 2015 | Phase 4 |
| NCT04672512 | Corcept Therapeutics |
Healthy
|
October 23, 2020 | Phase 1 |
| NCT02072863 | Amgen |
Multiple Myeloma
|
January 2014 | Phase 1|Phase 2 |
| NCT04598451 | argenx |
Pemphigus Vulgaris|Pemphigus Foliaceus
|
December 1, 2020 | Phase 3 |
| NCT05032183 | M.D. Anderson Cancer Center |
Recurrent Adult Lymphoblastic Lymphoma|Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Lymphoblastic Lymphoma|Refractory T Acute Lymphoblastic Leukemia
|
February 17, 2022 | Phase 1|Phase 2 |
| NCT04903054 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|PPD |
Kidney Transplantation|Renal Transplant Recipients
|
October 2021 | Phase 2 |
| NCT04943146 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Ningbo Women & Children´s Hospital|People´s Hospital of Jinhua |
Thyroid Diseases
|
March 1, 2021 | |
| NCT05428826 | Assistance Publique - Hôpitaux de Paris |
Idiopathic Retroperitoneal Fibrosis
|
September 30, 2022 | Phase 4 |
| NCT00275509 | Johns Hopkins University |
Kidney Failure, Chronic
|
January 2007 | Phase 3 |
| NCT00938587 | Pfizer |
Rheumatoid Arthritis
|
October 2009 | Phase 2 |
| NCT00519285 | Sanofi|Regeneron Pharmaceuticals |
Prostatic Neoplasms|Neoplasm Metastasis
|
August 2007 | Phase 3 |
| NCT00003232 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Pain|Prostate Cancer|Quality of Life
|
November 24, 1997 | Phase 3 |
| NCT04479267 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma w+MYC & BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma w+MYC, BCL2 & BCL6 Rearrangements
|
August 21, 2020 | Phase 2 |
| NCT04568837 | Oregon Health and Science University |
Spine Fusion
|
March 1, 2021 | Phase 4 |
| NCT01670084 | Mayo Clinic |
B-cell Adult Acute Lymphoblastic Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia
|
December 2012 | Phase 2 |
| NCT00893048 | Milton S. Hershey Medical Center |
Cellulitis|Erysipelas
|
January 15, 2010 | Phase 2 |
| NCT00066469 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoproliferative Disorder
|
April 2004 | Phase 2 |
| NCT02661503 | University of Cologne |
Classical Hodgkin Lymphoma
|
July 2016 | Phase 3 |
| NCT05211336 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)|Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
|
April 19, 2022 | Phase 1 |
| NCT01210677 | Ottawa Heart Institute Research Corporation |
Cardiac Sarcoidosis|Sarcoidosis
|
April 2014 | Phase 4 |
| NCT01750866 | Case Comprehensive Cancer Center |
Castrate-resistant Metastatic Prostate Cancer
|
February 2013 | Phase 2 |
| NCT00217425 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
July 2006 | Phase 2 |
| NCT00799539 | Janssen-Ortho Inc., Canada|Ortho Biotech Canada |
Multiple Myeloma
|
||
| NCT00080925 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
February 2004 | Phase 1 |
| NCT05600686 | Joseph Tuscano|National Cancer Institute (NCI)|ADC Therapeutics|University of California, Davis |
Double-Expressor Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
|
December 1, 2022 | Phase 2 |
| NCT04594798 | University of Rochester|Genentech, Inc. |
DLBCL|Lymphoma, B-Cell
|
September 20, 2021 | Phase 2 |
| NCT01503229 | University of Washington|National Cancer Institute (NCI) |
Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Adenocarcinoma
|
December 2012 | Phase 2 |
| NCT01106833 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program |
Chronic GVHD
|
April 2010 | Phase 2|Phase 3 |
| NCT00309881 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
April 2003 | Phase 2 |
| NCT00002556 | National Cancer Institute (NCI) |
Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
July 1994 | Phase 3 |
| NCT01371630 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Burkitt-Like Lymphoma With 11q Aberration|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Burkitt Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Burkitt Lymphoma
|
August 26, 2011 | Phase 1|Phase 2 |
| NCT00003578 | Lymphoma Trials Office|National Cancer Institute (NCI) |
Lymphoma
|
January 1993 | Phase 3 |
| NCT04663347 | Genmab|AbbVie |
Diffuse Large B-Cell Lymphoma|Follicular Lymphoma
|
November 16, 2020 | Phase 1|Phase 2 |
| NCT00550550 | ALK-Abelló A+S |
Rhinoconjunctivitis|Rhinitis|Conjunctivitis|Allergy
|
November 2007 | Phase 3 |
| NCT03715699 | Peking Union Medical College Hospital |
Autoimmune Disease
|
July 1, 2018 | Not Applicable |
| NCT00006054 | Fairview University Medical Center|Office of Rare Diseases (ORD) |
Immunologic Deficiency Syndromes|Chediak-Higashi Syndrome|Common Variable Immunodeficiency|Graft Versus Host Disease|X-Linked Lymphoproliferative Syndrome|Familial Erythrophagocytic Lymphohistiocytosis|Hemophagocytic Lymphohistiocytosis|X-linked Agammaglobulinemia|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|X-linked Hyper IgM Syndrome|Severe Combined Immunodeficiency|Leukocyte Adhesion Deficiency Syndrome|Virus-Associated Hemophagocytic Syndrome
|
March 2000 | Not Applicable |
| NCT02268149 | Boehringer Ingelheim |
Healthy
|
April 2000 | Phase 1 |
| NCT00424749 | Fernando Fervenza|Genentech, Inc.|Biogen|National Center for Research Resources (NCRR)|Mayo Clinic |
Churg-Strauss Syndrome
|
June 2007 | Phase 2 |
| NCT00306670 | Georgetown University|Genentech, Inc. |
Hemophilia A
|
April 2006 | Phase 2|Phase 3 |
| NCT04558268 | Soroka University Medical Center |
Recurrent Pregnancy Loss(RPL)|Recurrent Miscarriage
|
December 2020 | Phase 2|Phase 3 |
| NCT01400464 | University Hospital, Caen |
Giant Cell Arteritis
|
July 2009 | Phase 4 |
| NCT00072007 | Swiss Group for Clinical Cancer Research |
Leukemia
|
June 2002 | Phase 2 |
| NCT01235689 | AbbVie (prior sponsor, Abbott)|AbbVie |
Crohn´s Disease
|
February 11, 2011 | Phase 3 |
| NCT01000285 | Washington University School of Medicine |
Leukemia-Lymphoma, Adult T-Cell
|
September 2010 | Phase 1|Phase 2 |
| NCT01780844 | Astellas Pharma Global Development, Inc.|Kyowa Kirin Co., Ltd.|Astellas Pharma Inc |
Kidney Transplantation
|
March 5, 2013 | Phase 2 |
| NCT01961843 | Massachusetts General Hospital |
Prostate Cancer
|
October 2013 | Not Applicable |
| NCT02949284 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) |
Stage II Prostate Adenocarcinoma|Stage III Prostate Adenocarcinoma
|
June 20, 2017 | Phase 2 |
| NCT04658927 | Warrenville Eyecare |
Meibomian Gland Dysfunction|Evaporative Dry Eye
|
January 4, 2021 | Phase 4 |
| NCT01359592 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
September 2011 | Phase 2 |
| NCT03914625 | National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Down Syndrome
|
June 28, 2019 | Phase 3 |
| NCT04301076 | National Cancer Institute (NCI) |
Acute Adult T-Cell Leukemia+Lymphoma|Adult T-Cell Leukemia+Lymphoma|Chronic Adult T-Cell Leukemia+Lymphoma|HTLV-1 Infection
|
June 15, 2020 | Phase 1 |
| NCT00551928 | Fondazione EMN Italy Onlus |
Multiple Myeloma|Newly Diagnosed Patients
|
June 2007 | Phase 3 |
| NCT01309672 | Southwest Oncology Group|National Cancer Institute (NCI) |
Prostate Cancer
|
August 9, 2011 | Phase 2 |
| NCT00634647 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Prostate Cancer|Genetic Polymorphism
|
February 19, 2008 | Phase 2 |
| NCT02159690 | Kenneth Pienta, MD|Prostate Cancer Foundation Norway|Johns Hopkins University |
Prostate Cancer|Localized Prostate Cancer
|
September 2014 | Phase 2 |
| NCT00006890 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Multiple Myeloma and Plasma Cell Neoplasm
|
July 12, 2000 | Phase 2 |
| NCT00049673 | NCIC Clinical Trials Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Canadian Cancer Trials Group |
Multiple Myeloma and Plasma Cell Neoplasm
|
September 16, 2002 | Phase 3 |
| NCT00634179 | Emory University|Millennium Pharmaceuticals, Inc. |
Lymphoma, B-Cell|Follicular Lymphoma
|
February 2008 | Phase 1|Phase 2 |
| NCT00039130 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
May 2002 | Phase 2 |
| NCT04748042 | University of Michigan Rogel Cancer Center |
Prostate Cancer|Castrate Sensitive Prostate Cancer|Oligometastatic Disease
|
May 28, 2021 | Phase 2 |
| NCT01856192 | National Cancer Institute (NCI) |
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
|
August 27, 2013 | Phase 2 |
| NCT03093272 | Dana-Farber Cancer Institute|Janssen Pharmaceuticals |
Prostate Cancer
|
June 23, 2017 | Phase 2 |
| NCT00571675 | Ascenta Therapeutics |
Hormone Refractory Prostate Cancer
|
October 2007 | Phase 2 |
| NCT03952637 | National Human Genome Research Institute (NHGRI)|Sio Gene Therapies|National Institutes of Health Clinical Center (CC) |
Lysosomal Diseases|Gangliosidosis|GM1
|
August 19, 2019 | Phase 1|Phase 2 |
| NCT02077634 | Universität des Saarlandes |
Prostate Cancer
|
May 2014 | Phase 2 |
| NCT00987116 | Assistance Publique - Hôpitaux de Paris |
Myasthenia Gravis
|
June 2009 | Phase 4 |
| NCT02921789 | Astellas Pharma Global Development, Inc.|Kyowa Kirin Co., Ltd.|Astellas Pharma Inc |
Kidney Transplantation|Primary Focal Segmental Glomerulosclerosis (FSGS)
|
May 22, 2017 | Phase 2 |
| NCT00541281 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Sanofi |
Hormone Resistant Prostate Cancer|Metastatic Prostate Cancer
|
December 2003 | Phase 2 |
| NCT01777152 | Seagen Inc.|Millennium Pharmaceuticals, Inc. |
Anaplastic Large-Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Lymphoma
|
January 31, 2013 | Phase 3 |
| NCT01888952 | Anand B. Karnad|The University of Texas Health Science Center at San Antonio |
Advanced B-cell Lymphoid Malignancies
|
July 2013 | Early Phase 1 |
| NCT04501367 | Kovach Eye Institute |
Vitrectomy|Macular Pucker|Retinal Edema
|
August 20, 2020 | Phase 4 |
| NCT00000147 | National Eye Institute (NEI) |
Multiple Sclerosis|Optic Neuritis
|
July 1988 | Not Applicable |
| NCT01758120 | Guangdong Provincial People´s Hospital |
IgA Nephropathy
|
December 2012 | Phase 4 |
| NCT05247554 | Assistance Publique - Hôpitaux de Paris |
Pulmonary Sarcoidosis
|
March 1, 2022 | Phase 3 |
| NCT01998971 | Janssen Research & Development, LLC |
Multiple Myeloma
|
February 18, 2014 | Phase 1 |
| NCT03678025 | Southwest Oncology Group|National Cancer Institute (NCI) |
Castration Levels of Testosterone|Metastatic Prostatic Adenocarcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8
|
September 17, 2018 | Phase 3 |
| NCT05406401 | Merck Sharp & Dohme LLC |
Lymphoma, Large B-Cell, Diffuse (DLBCL)
|
July 14, 2022 | Phase 2 |
| NCT00005964 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
May 2000 | Phase 2 |
| NCT02689960 | Wuerzburg University Hospital |
Adrenal Insufficiency
|
January 2017 | Phase 2 |
| NCT00271791 | Carmel Medical Center|Clalit Health Services, Haifa and West Galilee|Hillel Yaffe Medical Center|Rambam Health Care Campus|University Health Network, Toronto |
Vestibular Diseases|Vestibular Neuronitis
|
September 2005 | Phase 2 |
| NCT00352027 | St. Jude Children´s Research Hospital |
Hodgkin´s Lymphoma
|
July 20, 2006 | Phase 2 |
| NCT00170196 | Medical Center Alkmaar |
Pneumonia
|
August 2005 | Phase 3 |
| NCT03367663 | Prof. Tony hayek MD|Rambam Health Care Campus |
Atherosclerosis|Dyslipidemias|Diabetes
|
January 17, 2018 | Early Phase 1 |
| NCT04432714 | The First Affiliated Hospital with Nanjing Medical University |
DLBCL|Untreated|MYC Gene Rearrangement
|
June 9, 2020 | Phase 1|Phase 2 |
| NCT00726700 | Universität des Saarlandes |
Lymphoma
|
May 2004 | Phase 2 |
| NCT00406978 | Silvio Aime|University of Turin, Italy |
Multiple Myeloma
|
February 2006 | Phase 1|Phase 2 |
| NCT05101928 | Ottawa Hospital Research Institute |
Uveitis, Posterior|Uveitis, Intermediate|Panuveitis
|
December 1, 2021 | Phase 4 |
| NCT00058084 | National Cancer Institute (NCI) |
Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage IV Prostate Cancer
|
March 2003 | Phase 2 |
| NCT00070018 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
February 2004 | Phase 2 |
| NCT01867710 | Janssen Pharmaceutica N.V., Belgium |
Prostate Cancer
|
July 16, 2013 | Phase 2 |
| NCT00419926 | Novartis |
Kidney Transplantation
|
December 2006 | Phase 4 |
| NCT04922567 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Ruijin Hospital|Xinqiao Hospital of Chongqing|Union hospital of Fujian Medical University|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Southern Medical University, China|Shandong Provincial Hospital|Huashan Hospital|First Hospital of China Medical University|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Henan Provincial People´s Hospital|First Affiliated Hospital Xi´an Jiaotong University|Changhai Hospital|The Affiliated Hospital of Xuzhou Medical University|Wuhan Union Hospital, China|RenJi Hospital|Zhongda Hospital|The First Affiliated Hospital of Anhui Medical University|Hunan Cancer Hospital|First Affiliated Hospital of Harbin Medical University|Xiangya Hospital of Central South University|The First Affiliated Hospital of Dalian Medical University|Jilin Provincial Tumor Hospital|Shanxi Province Cancer Hospital|Zhongshan Hospital Xiamen University |
Peripheral T-Cell Lymphoma|Lenalidomide|CHOP
|
April 1, 2021 | Phase 2 |
| NCT00811031 | M.D. Anderson Cancer Center|Sanofi |
Prostate Cancer
|
Phase 2 | |
| NCT00350545 | Stanford University |
Graft vs Host Disease
|
August 2006 | Not Applicable |
| NCT04411654 | Prevail Therapeutics|Eli Lilly and Company |
Gaucher Disease, Type 2
|
June 29, 2021 | Phase 1|Phase 2 |
| NCT00705822 | Sanofi |
Prostatic Neoplasms
|
August 2006 | Phase 3 |
| NCT00003283 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Thymoma and Thymic Carcinoma
|
July 1998 | Phase 2 |
| NCT04726332 | Exelixis |
Neoplasm Malignant|Epithelial Ovarian Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Breast Carcinoma|Metastatic Castration-resistant Prostate Cancer
|
February 10, 2021 | Phase 1 |
| NCT03508635 | Corcept Therapeutics |
Healthy
|
September 2014 | Phase 1 |
| NCT01199900 | Pfizer |
Healthy
|
August 2010 | Phase 1 |
| NCT02380313 | GlaxoSmithKline |
Cancer
|
October 2015 | Phase 1 |
| NCT02228512 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease|Primary Effusion Lymphoma
|
August 15, 2014 | Phase 1|Phase 2 |
| NCT02261727 | The George Institute|National Health and Medical Research Council, Australia |
Chronic Obstructive Pulmonary Disease
|
June 2014 | Phase 4 |
| NCT02486952 | Hoffmann-La Roche|Serbian Lymphoma Group |
Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin´s Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
August 2005 | |
| NCT02081183 | Hoffmann-La Roche |
Lupus Nephritis
|
March 2006 | Phase 3 |
| NCT00720109 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
|
July 14, 2008 | Phase 2|Phase 3 |
| NCT00996502 | Columbia University|Genentech, Inc. |
Prostate Cancer
|
July 2006 | Phase 1|Phase 2 |
| NCT00069745 | Agennix |
Prostate Cancer|Hormone Refractory Prostate Cancer
|
September 2003 | Phase 3 |
| NCT00003783 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
March 1999 | Phase 2 |
| NCT03847272 | Centre Hospitalier Universitaire Dijon |
Patients With Newly Diagnosed Active NISU
|
August 1, 2019 | Phase 2 |
| NCT01717053 | Duke University|Janssen Pharmaceuticals |
Prostate Cancer
|
January 17, 2014 | Phase 2 |
| NCT03321890 | Sun Yat-sen University |
Peripheral T-cell Lymphoma
|
March 7, 2017 | Phase 2 |
| NCT04036721 | National Institute for Tuberculosis and Lung Diseases, Poland |
Lung Neoplasm Malignant|Interstitial Lung Disease
|
October 1, 2019 | Phase 4 |
| NCT01940276 | Duke University |
Prostate Cancer
|
October 2013 | Phase 2 |
| NCT00001256 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Inflammation|Vasculitis|Wegener´s Granulomatosis
|
March 1990 | Phase 2 |
| NCT00014755 | Fred Hutchinson Cancer Center|Office of Rare Diseases (ORD) |
Multiple Sclerosis
|
December 1997 | Phase 1 |
| NCT00002524 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
June 1993 | Phase 2 |
| NCT00136435 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Queen Elizabeth II Health Sciences Centre |
Acute Lymphoblastic Leukemia
|
June 2002 | Phase 2 |
| NCT02115997 | Hoffmann-La Roche |
Wegener´s Granulomatosis or Microscopic Polyangiitis
|
July 6, 2015 | Phase 4 |
| NCT03719105 | New York Medical College|University of Alabama at Birmingham |
NK-Cell Lymphoma|NK-Cell Leukemia|Peripheral T Cell Lymphoma
|
March 1, 2019 | Early Phase 1 |
| NCT04556617 | Opna-IO LLC |
Metastatic Castration-resistant Prostate Cancer
|
September 21, 2020 | Phase 1|Phase 2 |
| NCT00004231 | Northwestern University|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 2 |
| NCT01269021 | Zhi-Hong Liu, M.D.|Nanjing University School of Medicine |
IgA Nephropathy (IgAN)
|
November 2010 | Not Applicable |
| NCT01949337 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Astellas Pharma US, Inc.|Medivation, Inc.|Biologics, Inc. |
Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer
|
January 22, 2014 | Phase 3 |
| NCT04214626 | Henan Cancer Hospital |
Diffuse Large B Cell Lymphoma
|
January 2, 2020 | Phase 2 |
| NCT02914054 | Isfahan University of Medical Sciences|Adibvira |
ITP|Croticosteroid Therapy
|
October 1, 2016 | Phase 2|Phase 3 |
| NCT00087165 | University Health Network, Toronto|National Cancer Institute (NCI) |
Prostate Cancer
|
January 2005 | Phase 2 |
| NCT01308567 | Sanofi |
Prostate Cancer
|
May 5, 2011 | Phase 3 |
| NCT02182622 | Martin Gutierrez|Novartis|Hackensack Meridian Health |
Prostate Cancer
|
July 2014 | Phase 1 |
| NCT04869371 | Hongqian Guo|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Neoadjuvant Therapy High Risk Prostate Cancer Docetaxel
|
December 12, 2018 | Phase 2 |
| NCT00507416 | Millennium Pharmaceuticals, Inc. |
Multiple Myeloma
|
June 2007 | Phase 3 |
| NCT00002785 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
July 1996 | Phase 2 |
| NCT02370550 | Peking University People´s Hospital |
Sjogren´s Syndrome
|
March 2015 | Phase 4 |
| NCT00557193 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Undifferentiated Leukemia|Childhood T Acute Lymphoblastic Leukemia
|
January 14, 2008 | Phase 3 |
| NCT05455697 | University of Washington |
Diffuse Large B-Cell Lymphoma|Grade 3b Follicular Lymphoma|High Grade B-Cell Lymphoma
|
December 15, 2022 | Phase 1|Phase 2 |
| NCT04146207 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
Chronic GVHD
|
April 2, 2020 | Early Phase 1 |
| NCT00043979 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Sarcoma
|
September 19, 2002 | Phase 2 |
| NCT01594918 | Rahul Aggarwal|Sanofi|University of California, San Francisco |
Metastatic Castration-resistant Prostate Cancer
|
June 2012 | Phase 1 |
| NCT01033864 | Hoffmann-La Roche |
Kidney Transplantation
|
November 2009 | Phase 4 |
| NCT01356511 | Shandong University|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Peking Union Medical College Hospital|Ruijin Hospital|Wuhan Union Hospital, China|Tongji Hospital|Shandong University of Traditional Chinese Medicine|Anhui Provincial Hospital|Zhejiang Provincial Hospital of TCM|Second Hospital of Shanxi Medical University|People´s Hospital of Xinjiang Uygur Autonomous Region|Shenzhen Second People´s Hospital |
Purpura, Thrombocytopenic, Idiopathic
|
September 2010 | Phase 4 |
| NCT00290498 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
August 1, 2005 | Phase 2 |
| NCT01622439 | Lund University Hospital|Valcuria |
Diffuse Large B-cell Lymphoma
|
June 2012 | Phase 1|Phase 2 |
| NCT03853044 | Ruijin Hospital |
Angioimmunoblastic T-cell Lymphoma
|
December 29, 2018 | Phase 2 |
| NCT02199184 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
AIDS-Related Burkitt Lymphoma|Atypical Burkitt+Burkitt-Like Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent Acute Lymphoblastic Leukemia|Recurrent Burkitt Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Burkitt Lymphoma
|
January 14, 2015 | Phase 2 |
| NCT01884571 | Emory University|ALS Association |
Amyotrophic Lateral Sclerosis (ALS)
|
October 2013 | Phase 2 |
| NCT00101101 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Lymphoma Research Foundation|Novartis |
Lymphoma
|
July 2004 | Phase 2 |
| NCT00973752 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Enzon Pharmaceuticals, Inc.|Genzyme, a Sanofi Company |
Acute Lymphoblastic Leukemia
|
August 2009 | Phase 2 |
| NCT00671034 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
July 21, 2008 | Phase 3 |
| NCT00290667 | German High-Grade Non-Hodgkin´s Lymphoma Study Group|Universität des Saarlandes |
Lymphoma
|
February 2004 | Phase 2 |
| NCT01237249 | PETHEMA Foundation|Janssen-Cilag Ltd.|Celgene|TFS Trial Form Support |
Multiple Myeloma
|
February 2011 | Phase 2 |
| NCT01785979 | Lihir Medical Centre |
Hyper-reactive Malarial Splenomegaly|Malaria|Anaemia
|
January 2016 | Phase 3 |
| NCT02073097 | Case Comprehensive Cancer Center |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
January 28, 2015 | Phase 1|Phase 2 |
| NCT04066114 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Clinical Trials in Organ Transplantation |
Living-Donor Kidney Transplant|Kidney Transplant Recipients
|
December 11, 2019 | Phase 1|Phase 2 |
| NCT04517435 | Deepa Jagadeesh|Case Comprehensive Cancer Center |
Diffuse Large B-Cell Lymphoma
|
April 28, 2021 | Phase 1|Phase 2 |
| NCT00657410 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Nonneoplastic Condition
|
April 2008 | Phase 3 |
| NCT02532790 | Nanjing Children´s Hospital |
Henoch-Schoenlein Purpura Nephritis
|
August 2015 | Phase 2 |
| NCT04438382 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Steroid-Refractory Pneumonitis
|
January 7, 2021 | Phase 2 |
| NCT00041327 | AIDS Malignancy Consortium|National Cancer Institute (NCI) |
Lymphoma
|
October 2002 | Phase 2 |
| NCT01193842 | National Cancer Institute (NCI) |
AIDS-Related Plasmablastic Lymphoma|AIDS-Related Primary Effusion Lymphoma|Ann Arbor Stage I Diffuse Large B-Cell Lymphoma|Ann Arbor Stage I Grade 3 Follicular Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma|HIV Infection|Plasmablastic Lymphoma|Primary Effusion Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma
|
October 6, 2010 | Phase 1|Phase 2 |
| NCT01687296 | GlaxoSmithKline |
Asthma
|
November 12, 2012 | Phase 3 |
| NCT00853008 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
January 2003 | Phase 4 |
| NCT01376401 | PETHEMA Foundation|Mundipharma Pharmaceuticals B.V.|Janssen-Cilag Ltd. |
Multiple Myeloma
|
July 2011 | Phase 2 |
| NCT01517802 | Janssen Research & Development, LLC |
Metastatic Castration-resistant Prostate Cancer|Metastatic Breast Cancer
|
March 28, 2012 | Phase 3 |
| NCT04745728 | Peking Union Medical College Hospital |
Idiopathic Membranous Nephropathy
|
April 14, 2021 | Phase 3 |
| NCT02573012 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
March 29, 2016 | Phase 4 |
| NCT01578655 | Achieve Life Sciences |
Prostate Cancer
|
August 2012 | Phase 3 |
| NCT01809444 | Sun Yat-sen University |
Thyroid Associated Opthalmopathies
|
November 2012 | Phase 2|Phase 3 |
| NCT00002571 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
June 1994 | Phase 2 |
| NCT00715208 | Millennium Pharmaceuticals, Inc. |
Relapsed Follicular Lymphoma
|
September 2008 | Phase 2 |
| NCT00772668 | University of Miami |
Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma
|
September 25, 2009 | Not Applicable |
| NCT04766996 | Emory University |
Anesthesia|Opioid Use
|
May 17, 2021 | Phase 4 |
| NCT01539174 | Fox Chase Cancer Center|Genentech, Inc. |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
Phase 2 | |
| NCT04626791 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Mantle Cell Lymphoma
|
August 3, 2021 | Phase 2 |
| NCT03036904 | Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center |
Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma
|
February 6, 2017 | Phase 1 |
| NCT04127578 | Prevail Therapeutics|Eli Lilly and Company |
Parkinson Disease
|
January 3, 2020 | Phase 1|Phase 2 |
| NCT01619813 | Canadian Cancer Trials Group|Oncolytics Biotech |
Prostate Cancer
|
July 11, 2012 | Phase 2 |
| NCT00302003 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Favorable Prognosis Hodgkin Lymphoma|Childhood Lymphocyte Depletion Hodgkin Lymphoma|Childhood Mixed Cellularity Hodgkin Lymphoma|Childhood Nodular Sclerosis Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma
|
February 2006 | Phase 3 |
| NCT01425099 | ViiV Healthcare|Shionogi|GlaxoSmithKline |
Infection, Human Immunodeficiency Virus
|
September 2011 | Phase 1 |
| NCT01148446 | Fondazione Italiana Linfomi ONLUS |
Elderly Patients (>65 Years)|Diffuse Large B Cell Lymphoma (DLBCL)
|
January 2003 | Phase 3 |
| NCT00282347 | Genentech, Inc. |
Lupus Nephritis
|
January 2006 | Phase 3 |
| NCT00853411 | University of Pittsburgh |
Asthma
|
December 2008 | Not Applicable |
| NCT04666129 | Myovant Sciences GmbH |
Metastatic Castration-Resistant Prostate Cancer|Metastatic Castration-Sensitive Prostate Cancer|Non-Metastatic Castration-Resistant Prostate Cancer
|
February 18, 2021 | Phase 1 |
| NCT02861573 | Merck Sharp & Dohme LLC |
Metastatic Castration-Resistant Prostate Cancer
|
November 17, 2016 | Phase 1|Phase 2 |
| NCT00209209 | European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association|HOVON - Dutch Haemato-Oncology Association|Nordic Lymphoma Group |
Lymphoma, Mantle-Cell
|
January 14, 2004 | Phase 3 |
| NCT01829295 | University of California, San Francisco|Aravind Eye Hospitals, India|Oregon Health and Science University|Asociación para Evitar la Ceguera en México|Royal Victoria Eye and Ear Hospital|Northwestern University|National Eye Institute (NEI)|King Khaled Eye Specialist Hospital |
Uveitis
|
August 2013 | Phase 3 |
| NCT02414568 | The Lymphoma Academic Research Organisation |
Classical Hodgkin Lymphoma
|
July 17, 2015 | Phase 2 |
| NCT00225173 | Stanford University|National Cancer Institute (NCI) |
Hodgkin Disease
|
October 2001 | Phase 2 |
| NCT00598858 | John P. Fruehauf|Sanofi|University of California, Irvine |
Prostate Cancer|Adenocarcinoma of the Prostate|Stage I Prostate Cancer|Stage II Prostate Cancer
|
January 2009 | Phase 2 |
| NCT04359511 | University Hospital, Tours |
COVID-19
|
July 3, 2020 | Phase 3 |
| NCT00149994 | Novartis Pharmaceuticals|Novartis |
Liver Transplant
|
December 2002 | Phase 4 |
| NCT00051311 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Hematologic Neoplasms
|
January 3, 2003 | Phase 2 |
| NCT00016302 | National Cancer Institute (NCI) |
T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia
|
April 2001 | Not Applicable |
| NCT00003595 | National Cancer Institute (NCI) |
Lymphoma
|
January 1999 | Phase 3 |
| NCT00445900 | Mayo Clinic|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Secondary Myelofibrosis
|
October 2004 | Phase 2 |
| NCT00264953 | University of Cologne |
Hodgkin´s Lymphoma
|
May 1998 | Phase 3 |
| NCT01612377 | Zalicus |
Rheumatoid Arthritis
|
March 2012 | Phase 2 |
| NCT02119273 | Loma Linda University |
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
|
September 2014 | Phase 4 |
| NCT03755804 | St. Jude Children´s Research Hospital|Teva Pharmaceuticals USA|Seagen Inc. |
Hodgkin Lymphoma
|
December 12, 2018 | Phase 2 |
| NCT00278408 | German High-Grade Non-Hodgkin´s Lymphoma Study Group |
Lymphoma
|
November 2005 | Phase 3 |
| NCT03023358 | Nanfang Hospital of Southern Medical University |
Peripheral T Cell Lymphoma
|
February 2017 | Phase 3 |
| NCT03742258 | Northwestern University|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma
|
March 13, 2019 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL ( 348.74 mM ; ultrasonic and warming and heat to 80°C)
H 2 O : 1 mg/mL ( 2.79 mM ; ultrasonic and warming and heat to 80°C)
Preparing
Stock Solutions
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7899 mL | 13.9497 mL | 27.8995 mL |
| 5 mM | 0.5580 mL | 2.7899 mL | 5.5799 mL |
| 10 mM | 0.2790 mL | 1.3950 mL | 2.7899 mL |
*
Please refer to the solubility information to select the appropriate solvent.
In Vivo:
*
All of the co-solvents are available by MCE.
References
- [1] RIEMER AD. Application of the newer corticosteroids to augment diuresis in congestive heart failure. Am J Cardiol. 1958 Apr;1(4):488-96.
- [2] [2]N Tomioka, et al. Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol. 1986 Apr;7(4):868-72.
- [3] Qianqian Li, et al. Metabolic Profiling Reveals an Abnormal Pattern of Serum Fatty Acids in MRL/lpr Mice Under Treatment With Prednisone. Front Pharmacol. 2020 Feb 25;11:115.
Synonyms
Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy-
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
Ancortone
Bicortone
Colisone
Δ1-Cortisone
Dacortin
Decortancyl
Decortisyl
Δ1-Dehydrocortisone
1-Dehydrocortisone
Dekortin
Delta E
Delta-Cortelan
Deltacortisone
Deltacortone
Deltasone
Deltisone
Deltra
Di-Adreson
17α,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
Encortone
Enkorton
Hostacortin
Metacortandracin
Meticorten
Paracort
Prednisone
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
Supercortil
Ultracorten
Ultracortene
Encorton
1,2-Dehydrocortisone
Dehydrocortisone
Δ-Cortisone
17,21-Dihydroxypregn-1,4-diene-3,11,20-trione
NSC 10023
Cortidelt
Prednison
Deltison
Rectodelt
Prednitone
Me-Korti
Prednicorm
Cartancyl
Uniplen
Prednicort
Liquid Pred
Pehacort
Adasone
Drazone
Apo-Prednisone
Winpred
Econosone
Fernisone
Delta-Dome
Nisona
Deltisona
Panafcort
Prednicot
Deltacortene
Dacorten
Prednidib
Sterapred
Cordrol
Prednicen M
Panasol
Predniment
Cortan
Dellacort
Dellacort A
Sone
Orasone
Delcortin
Decortin
Parmenison
Pulmison
Nurison
Retrocortine
Pronison
Prednilonga
17α,21-Dihydroxypregn-1,4-dien-3,11,20-trione
Prednidone
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.